1
|
Nakajima S, Demers G, Machuca-Parra AI, Pour ZD, Bairamian D, Bouyakdan K, Fisette A, Kabahizi A, Robb J, Rodaros D, Laurent C, Ferreira G, Arbour N, Alquier T, Fulton S. Central activation of the fatty acid sensor GPR120 suppresses microglia reactivity and alleviates sickness- and anxiety-like behaviors. J Neuroinflammation 2023; 20:302. [PMID: 38111048 PMCID: PMC10729532 DOI: 10.1186/s12974-023-02978-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Accepted: 11/29/2023] [Indexed: 12/20/2023] Open
Abstract
G protein-coupled receptor 120 (GPR120, Ffar4) is a sensor for long-chain fatty acids including omega-3 polyunsaturated fatty acids (n-3 PUFAs) known for beneficial effects on inflammation, metabolism, and mood. GPR120 mediates the anti-inflammatory and insulin-sensitizing effects of n-3 PUFAs in peripheral tissues. The aim of this study was to determine the impact of GPR120 stimulation on microglial reactivity, neuroinflammation and sickness- and anxiety-like behaviors by acute proinflammatory insults. We found GPR120 mRNA to be enriched in both murine and human microglia, and in situ hybridization revealed GPR120 expression in microglia of the nucleus accumbens (NAc) in mice. In a manner similar to or exceeding n-3 PUFAs, GPR120 agonism (Compound A, CpdA) strongly attenuated lipopolysaccharide (LPS)-induced proinflammatory marker expression in primary mouse microglia, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and inhibited nuclear factor-ĸB translocation to the nucleus. Central administration of CpdA to adult mice blunted LPS-induced hypolocomotion and anxiety-like behavior and reduced TNF-α, IL-1β and IBA-1 (microglia marker) mRNA in the NAc, a brain region modulating anxiety and motivation and implicated in neuroinflammation-induced mood deficits. GPR120 agonist pre-treatment attenuated NAc microglia reactivity and alleviated sickness-like behaviors elicited by central injection TNF-α and IL-1β. These findings suggest that microglial GPR120 contributes to neuroimmune regulation and behavioral changes in response to acute infection and elevated brain cytokines. GPR120 may participate in the protective action of n-3 PUFAs at the neural and behavioral level and offers potential as treatment target for neuroinflammatory conditions.
Collapse
Affiliation(s)
- Shingo Nakajima
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
| | - Geneviève Demers
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
- Department of Nutrition, Université de Montréal, Montréal, QC, H3T1J4, Canada
| | - Arturo Israel Machuca-Parra
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
| | - Zahra Dashtehei Pour
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
- Department of Nutrition, Université de Montréal, Montréal, QC, H3T1J4, Canada
| | - Diane Bairamian
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
- Department of Nutrition, Université de Montréal, Montréal, QC, H3T1J4, Canada
| | - Khalil Bouyakdan
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
| | - Alexandre Fisette
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
- Research Group in Cellular Signaling, Department of Medical Biology, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - Anita Kabahizi
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
- Department of Nutrition, Université de Montréal, Montréal, QC, H3T1J4, Canada
| | - Josephine Robb
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
| | - Demetra Rodaros
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
| | - Cyril Laurent
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
- Department of Neuroscience, Université de Montréal, Montréal, QC, H3T1J4, Canada
| | - Guillaume Ferreira
- Nutrition and Integrative Neurobiology Unit, UMR 1286, INRA-Université de Bordeaux, Bordeaux, France
| | - Nathalie Arbour
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
- Department of Neuroscience, Université de Montréal, Montréal, QC, H3T1J4, Canada
| | - Thierry Alquier
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada
- Department of Medicine, Université de Montréal, Montréal, QC, H3T1J4, Canada
| | - Stephanie Fulton
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, H3T1J4, Canada.
- Department of Nutrition, Université de Montréal, Montréal, QC, H3T1J4, Canada.
| |
Collapse
|
2
|
Béland-Millar A, Kirby A, Truong Y, Ouellette J, Yandiev S, Bouyakdan K, Pileggi C, Naz S, Yin M, Carrier M, Kotchetkov P, St-Pierre MK, Tremblay MÈ, Courchet J, Harper ME, Alquier T, Messier C, Shuhendler AJ, Lacoste B. 16p11.2 haploinsufficiency reduces mitochondrial biogenesis in brain endothelial cells and alters brain metabolism in adult mice. Cell Rep 2023; 42:112485. [PMID: 37149866 DOI: 10.1016/j.celrep.2023.112485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 02/20/2023] [Accepted: 04/22/2023] [Indexed: 05/09/2023] Open
Abstract
Neurovascular abnormalities in mouse models of 16p11.2 deletion autism syndrome are reminiscent of alterations reported in murine models of glucose transporter deficiency, including reduced brain angiogenesis and behavioral alterations. Yet, whether cerebrovascular alterations in 16p11.2df/+ mice affect brain metabolism is unknown. Here, we report that anesthetized 16p11.2df/+ mice display elevated brain glucose uptake, a phenomenon recapitulated in mice with endothelial-specific 16p11.2 haplodeficiency. Awake 16p11.2df/+ mice display attenuated relative fluctuations of extracellular brain glucose following systemic glucose administration. Targeted metabolomics on cerebral cortex extracts reveals enhanced metabolic responses to systemic glucose in 16p11.2df/+ mice that also display reduced mitochondria number in brain endothelial cells. This is not associated with changes in mitochondria fusion or fission proteins, but 16p11.2df/+ brain endothelial cells lack the splice variant NT-PGC-1α, suggesting defective mitochondrial biogenesis. We propose that altered brain metabolism in 16p11.2df/+ mice is compensatory to endothelial dysfunction, shedding light on previously unknown adaptative responses.
Collapse
Affiliation(s)
- Alexandria Béland-Millar
- Neuroscience Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; School of Psychology, University of Ottawa, Ottawa, ON, Canada
| | - Alexia Kirby
- Faculty of Science, Department of Biology, University of Ottawa, Ottawa, ON, Canada
| | - Yen Truong
- Faculty of Science, Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON, Canada
| | - Julie Ouellette
- Neuroscience Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Faculty of Medicine, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Sozerko Yandiev
- University Lyon 1, CNRS, INSERM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, U1315, Institut NeuroMyoGène, 69008 Lyon, France
| | - Khalil Bouyakdan
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Department of Medicine Université de Montréal, Montreal, QC, Canada
| | - Chantal Pileggi
- Faculty of Medicine, Department of Biochemistry Microbiology and Immunology, Ottawa, ON, Canada
| | - Shama Naz
- University of Ottawa Metabolomics Core Facility, Faculty of Medicine, Ottawa, ON, Canada
| | - Melissa Yin
- FUJIFILM VisualSonics, Inc, Toronto, ON, Canada
| | - Micaël Carrier
- Division of Medical Sciences, University of Victoria, Victoria, BC, Canada
| | - Pavel Kotchetkov
- Neuroscience Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Faculty of Medicine, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada
| | | | - Marie-Ève Tremblay
- Division of Medical Sciences, University of Victoria, Victoria, BC, Canada; Neurology and Neurosurgery Department, McGill University, Montreal, QC, Canada; Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, BC, Canada
| | - Julien Courchet
- University Lyon 1, CNRS, INSERM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, U1315, Institut NeuroMyoGène, 69008 Lyon, France
| | - Mary-Ellen Harper
- Faculty of Medicine, Department of Biochemistry Microbiology and Immunology, Ottawa, ON, Canada
| | - Thierry Alquier
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Department of Medicine Université de Montréal, Montreal, QC, Canada
| | - Claude Messier
- School of Psychology, University of Ottawa, Ottawa, ON, Canada
| | - Adam J Shuhendler
- Faculty of Science, Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON, Canada; University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada
| | - Baptiste Lacoste
- Neuroscience Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Faculty of Medicine, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada; University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada.
| |
Collapse
|
3
|
Bouyakdan K, Manceau R, Robb JL, Rodaros D, Fulton S, Alquier T. Role of astroglial ACBP in energy metabolism flexibility and feeding responses to metabolic challenges in male mice. J Neuroendocrinol 2022; 34:e13218. [PMID: 36471907 DOI: 10.1111/jne.13218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 10/26/2022] [Accepted: 11/10/2022] [Indexed: 11/19/2022]
Abstract
Acyl-CoA binding protein (ACBP), also known as diazepam binding inhibitor (DBI), has recently emerged as a hypothalamic and brainstem gliopeptide regulating energy balance. Previous work has shown that the ACBP-derived octadecaneuropeptide exerts strong anorectic action via proopiomelanocortin (POMC) neuron activation and the melanocortin-4 receptor. Importantly, targeted ACBP loss-of-function in astrocytes promotes hyperphagia and diet-induced obesity while its overexpression in arcuate astrocytes reduces feeding and body weight. Despite this knowledge, the role of astroglial ACBP in adaptive feeding and metabolic responses to acute metabolic challenges has not been investigated. Using different paradigms, we found that ACBP deletion in glial fibrillary acidic protein (GFAP)-positive astrocytes does not affect weight loss when obese male mice are transitioned from a high fat diet to a chow diet, nor metabolic parameters in mice fed with a normal chow diet (e.g., energy expenditure, body temperature) during fasting, cold exposure and at thermoneutrality. In contrast, astroglial ACBP deletion impairs meal pattern and feeding responses during refeeding after a fast and during cold exposure, thereby showing that ACBP is required to stimulate feeding in states of increased energy demand. These findings challenge the general view that astroglial ACBP exerts anorectic effects and suggest that regulation of feeding by ACBP is dependent on metabolic status.
Collapse
Affiliation(s)
- Khalil Bouyakdan
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine and Neurosciences and Nutrition, Université de Montréal, Montréal, Quebec, Canada
| | - Romane Manceau
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine and Neurosciences and Nutrition, Université de Montréal, Montréal, Quebec, Canada
| | - Josephine L Robb
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine and Neurosciences and Nutrition, Université de Montréal, Montréal, Quebec, Canada
| | - Demetra Rodaros
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine and Neurosciences and Nutrition, Université de Montréal, Montréal, Quebec, Canada
| | - Stephanie Fulton
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine and Neurosciences and Nutrition, Université de Montréal, Montréal, Quebec, Canada
| | - Thierry Alquier
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine and Neurosciences and Nutrition, Université de Montréal, Montréal, Quebec, Canada
| |
Collapse
|
4
|
Galipeau M, Jouvet N, Courty E, Vandenbeek R, Khan N, Bouyakdan K, Nian C, Iorio C, Scott D, Faraj M, Oeffinger M, Lynn F, Screaton R, Alquier T, Estall J. The Diabetes-Related Gly482Ser Polymorphism Affects PGC1A Stability and Glucose Metabolism. Can J Diabetes 2022. [DOI: 10.1016/j.jcjd.2022.09.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
5
|
Jouvet N, Bouyakdan K, Campbell SA, Baldwin C, Townsend SE, Gannon MA, Poitout V, Alquier T, Estall JL. The Tetracycline-Controlled Transactivator (Tet-On/Off) System in β-Cells Reduces Insulin Expression and Secretion in Mice. Diabetes 2021; 70:2850-2859. [PMID: 34610983 PMCID: PMC8660978 DOI: 10.2337/db21-0147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 09/29/2021] [Indexed: 11/13/2022]
Abstract
Controllable genetic manipulation is an indispensable tool in research, greatly advancing our understanding of cell biology and physiology. However in β-cells, transgene silencing, low inducibility, ectopic expression, and off-targets effects are persistent challenges. In this study, we investigated whether an inducible Tetracycline (Tet)-Off system with β-cell-specific mouse insulin promoter (MIP)-itTA-driven expression of tetracycline operon (TetO)-CreJaw/J could circumvent previous issues of specificity and efficacy. Following assessment of tissue-specific gene recombination, β-cell architecture, in vitro and in vivo glucose-stimulated insulin secretion, and whole-body glucose homeostasis, we discovered that expression of any tetracycline-controlled transactivator (e.g., improved itTA, reverse rtTA, or tTA) in β-cells significantly reduced Insulin gene expression and decreased insulin content. This translated into lower pancreatic insulin levels and reduced insulin secretion in mice carrying any tTA transgene, independent of Cre recombinase expression or doxycycline exposure. Our study echoes ongoing challenges faced by fundamental researchers working with β-cells and highlights the need for consistent and comprehensive controls when using the tetracycline-controlled transactivator systems (Tet-On or Tet-Off) for genome editing.
Collapse
Affiliation(s)
- Nathalie Jouvet
- Institut de recherches cliniques de Montréal (IRCM), Montréal, Quebec, Canada
| | - Khalil Bouyakdan
- Montreal Diabetes Research Centre, Centre de recherche du centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada
| | - Scott A Campbell
- Montreal Diabetes Research Centre, Centre de recherche du centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada
- Département de Médecine, Université de Montréal, Montréal, Quebec, Canada
| | - Cindy Baldwin
- Institut de recherches cliniques de Montréal (IRCM), Montréal, Quebec, Canada
| | - Shannon E Townsend
- Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN
| | - Maureen A Gannon
- Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN
- Department of Veterans Affairs, Tennessee Valley Health Authority, Nashville, TN
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Vincent Poitout
- Montreal Diabetes Research Centre, Centre de recherche du centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada
- Département de Médecine, Université de Montréal, Montréal, Quebec, Canada
| | - Thierry Alquier
- Montreal Diabetes Research Centre, Centre de recherche du centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada
- Département de Médecine, Université de Montréal, Montréal, Quebec, Canada
| | - Jennifer L Estall
- Institut de recherches cliniques de Montréal (IRCM), Montréal, Quebec, Canada
- Montreal Diabetes Research Centre, Centre de recherche du centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada
- Département de Médecine, Université de Montréal, Montréal, Quebec, Canada
| |
Collapse
|
6
|
Jouvet N, Courty É, Galipeau M, Vandenbeek R, Bouyakdan K, Alquier T, Estall J. Impact of the PGC-1α Gly482Ser Polymorphism on Mouse Metabolism. Can J Diabetes 2021. [DOI: 10.1016/j.jcjd.2021.09.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
7
|
Alquier T, Christian-Hinman CA, Alfonso J, Færgeman NJ. From benzodiazepines to fatty acids and beyond: revisiting the role of ACBP/DBI. Trends Endocrinol Metab 2021; 32:890-903. [PMID: 34565656 PMCID: PMC8785413 DOI: 10.1016/j.tem.2021.08.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 08/29/2021] [Accepted: 08/30/2021] [Indexed: 01/19/2023]
Abstract
Four decades ago Costa and colleagues identified a small, secreted polypeptide in the brain that can displace the benzodiazepine diazepam from the GABAA receptor, and was thus termed diazepam binding inhibitor (DBI). Shortly after, an identical polypeptide was identified in liver by its ability to induce termination of fatty acid synthesis, and was named acyl-CoA binding protein (ACBP). Since then, ACBP/DBI has been studied in parallel without a clear and integrated understanding of its dual roles. The first genetic loss-of-function models have revived the field, allowing targeted approaches to better understand the physiological roles of ACBP/DBI in vivo. We discuss the roles of ACBP/DBI in central and tissue-specific functions in mammals, with an emphasis on metabolism and mechanisms of action.
Collapse
Affiliation(s)
- Thierry Alquier
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine, Pharmacology and Physiology, Biochemistry, and Neurosciences, Université de Montréal, Montreal, QC, Canada.
| | - Catherine A Christian-Hinman
- Department of Molecular and Integrative Physiology, Neuroscience Program, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA
| | - Julieta Alfonso
- Department of Clinical Neurobiology, University Hospital Heidelberg and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | - Nils J Færgeman
- Department of Biochemistry and Molecular Biology, Villum Center for Bioanalytical Sciences, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark.
| |
Collapse
|
8
|
Diaz-Marin R, Crespo-Garcia S, Wilson AM, Buscarlet M, Dejda A, Fournier F, Juneau R, Alquier T, Sapieha P. Myeloid-resident neuropilin-1 influences brown adipose tissue in obesity. Sci Rep 2021; 11:15767. [PMID: 34344941 PMCID: PMC8333363 DOI: 10.1038/s41598-021-95064-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 07/20/2021] [Indexed: 11/09/2022] Open
Abstract
The beneficial effects of brown adipose tissue (BAT) on obesity and associated metabolic diseases are mediated through its capacity to dissipate energy as heat. While immune cells, such as tissue-resident macrophages, are known to influence adipose tissue homeostasis, relatively little is known about their contribution to BAT function. Here we report that neuropilin-1 (NRP1), a multiligand single-pass transmembrane receptor, is highly expressed in BAT-resident macrophages. During diet-induced obesity (DIO), myeloid-resident NRP1 influences interscapular BAT mass, and consequently vascular morphology, innervation density and ultimately core body temperature during cold exposure. Thus, NRP1-expressing myeloid cells contribute to the BAT homeostasis and potentially its thermogenic function in DIO.
Collapse
Affiliation(s)
- Roberto Diaz-Marin
- Department of Biochemistry, Maisonneuve-Rosemont Hospital Research Centre, Université de Montréal, 5415 Assumption Boulevard, Montréal, QC, H1T 2M4, Canada
| | - Sergio Crespo-Garcia
- Department of Biochemistry, Maisonneuve-Rosemont Hospital Research Centre, Université de Montréal, 5415 Assumption Boulevard, Montréal, QC, H1T 2M4, Canada
| | - Ariel M Wilson
- Department of Ophthalmology, Maisonneuve-Rosemont Research Centre, Université de Montréal, Montréal, QC, H1T2M4, Canada
| | - Manuel Buscarlet
- Department of Biochemistry, Maisonneuve-Rosemont Hospital Research Centre, Université de Montréal, 5415 Assumption Boulevard, Montréal, QC, H1T 2M4, Canada
| | - Agnieszka Dejda
- Department of Ophthalmology, Maisonneuve-Rosemont Research Centre, Université de Montréal, Montréal, QC, H1T2M4, Canada
| | - Frédérik Fournier
- Department of Biochemistry, Maisonneuve-Rosemont Hospital Research Centre, Université de Montréal, 5415 Assumption Boulevard, Montréal, QC, H1T 2M4, Canada
| | - Rachel Juneau
- Department of Biochemistry, Maisonneuve-Rosemont Hospital Research Centre, Université de Montréal, 5415 Assumption Boulevard, Montréal, QC, H1T 2M4, Canada
| | - Thierry Alquier
- Montreal Diabetes Research Centre and Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 rue Saint-Denis, Montréal, QC, H2X0A9, Canada
| | - Przemyslaw Sapieha
- Department of Biochemistry, Maisonneuve-Rosemont Hospital Research Centre, Université de Montréal, 5415 Assumption Boulevard, Montréal, QC, H1T 2M4, Canada. .,Department of Ophthalmology, Maisonneuve-Rosemont Research Centre, Université de Montréal, Montréal, QC, H1T2M4, Canada.
| |
Collapse
|
9
|
Majdoubi A, Lee JS, Kishta OA, Balood M, Moulefera MA, Ishido S, Talbot S, Cheong C, Alquier T, Thibodeau J. Lack of the E3 Ubiquitin Ligase March1 Affects CD8 T Cell Fate and Exacerbates Insulin Resistance in Obese Mice. Front Immunol 2020; 11:1953. [PMID: 32973799 PMCID: PMC7461985 DOI: 10.3389/fimmu.2020.01953] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Accepted: 07/20/2020] [Indexed: 01/08/2023] Open
Abstract
Obesity is a major risk factor for the development of insulin resistance and type 2 diabetes. However, the mechanisms that trigger the underlying adipose tissues inflammation are not completely understood. Here, we show that the E3 ubiquitin ligase March1 controls the phenotypic and functional properties of CD8+ T cells in mice white adipose tissue. In a diet-induced obesity model, mice lacking March1 [March1 knockout (KO)] show increased insulin resistance compared to their WT counterparts. Also, in obese March1 KO mice, the proportions of effector/memory (Tem) and resident/memory (Trm) CD8+ T cells were higher in the visceral adipose tissue, but not in the spleen. The effect of March1 on insulin resistance and on the phenotype of adipose tissue CD8+ T cells was independent of major histocompatibility complex class II ubiquitination. Interestingly, we adoptively transferred either WT or March1 KO splenic CD8+ T cells into obese WT chimeras that had been reconstituted with Rag1-deficient bone marrow. We observed an enrichment of Tem and Trm cells and exacerbated insulin resistance in mice that received March1 KO CD8 T cells. Mechanistically, we found that March1 deficiency alters the metabolic activity of CD8+ T cells. Our results provide additional evidence of the involvement of CD8+ T cells in adipose tissue inflammation and suggest that March1 controls the metabolic reprogramming of these cells.
Collapse
Affiliation(s)
- Abdelilah Majdoubi
- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada
| | - Jun Seong Lee
- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada
| | - Osama A Kishta
- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada
| | - Mohammad Balood
- Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, Canada
| | | | - Satoshi Ishido
- Department of Microbiology, Hyogo College of Medicine, Nishinomiya, Japan
| | - Sébastien Talbot
- Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, Canada
| | - Cheolho Cheong
- Institut de Recherches Cliniques de Montréal (IRCM), Montreal, QC, Canada
| | - Thierry Alquier
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Département de Médicine, Université de Montréal, Montreal, QC, Canada
| | - Jacques Thibodeau
- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada
| |
Collapse
|
10
|
Gesnik M, Bhatt M, Roy Cardinal MH, Destrempes F, Allard L, Nguyen BN, Alquier T, Giroux JF, Tang A, Cloutier G. In vivo Ultrafast Quantitative Ultrasound and Shear Wave Elastography Imaging on Farm-Raised Duck Livers during Force Feeding. Ultrasound Med Biol 2020; 46:1715-1726. [PMID: 32381381 DOI: 10.1016/j.ultrasmedbio.2020.03.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 02/05/2020] [Accepted: 03/10/2020] [Indexed: 06/11/2023]
Abstract
Shear wave elastography (speed and dispersion), local attenuation coefficient slope and homodyned-K parametric imaging were used for liver steatosis grading. These ultrasound biomarkers rely on physical interactions between shear and compression waves with tissues at both macroscopic and microscopic scales. These techniques were applied in a context not yet studied with ultrasound imaging, that is, monitoring steatosis of force-fed duck livers from pre-force-fed to foie gras stages. Each estimated feature presented a statistically significant trend along the feeding process (p values <10-3). However, whereas a monotonic increase in the shear wave speed was observed along the process, most quantitative ultrasound features exhibited an absolute maximum value halfway through the process. As the liver fat fraction in foie gras is much higher than that seen clinically, we hypothesized that a change in the ultrasound scattering regime is encountered for high-fat fractions, and consequently, care has to be taken when applying ultrasound biomarkers to grading of severe states of steatosis.
Collapse
Affiliation(s)
- Marc Gesnik
- Laboratory of Biorheology and Medical Ultrasonics, University of Montreal Hospital Research Center (CRCHUM), Montréal, QC, Canada
| | - Manish Bhatt
- Laboratory of Biorheology and Medical Ultrasonics, University of Montreal Hospital Research Center (CRCHUM), Montréal, QC, Canada
| | - Marie-Hélène Roy Cardinal
- Laboratory of Biorheology and Medical Ultrasonics, University of Montreal Hospital Research Center (CRCHUM), Montréal, QC, Canada
| | - François Destrempes
- Laboratory of Biorheology and Medical Ultrasonics, University of Montreal Hospital Research Center (CRCHUM), Montréal, QC, Canada
| | - Louise Allard
- Laboratory of Biorheology and Medical Ultrasonics, University of Montreal Hospital Research Center (CRCHUM), Montréal, QC, Canada
| | - Bich N Nguyen
- Service of Pathology, University of Montreal Hospital (CHUM), Montréal, QC, Canada
| | - Thierry Alquier
- CRCHUM and Montreal Diabetes Research Center, Montréal, QC, Canada; Department of Medicine, University of Montreal, Montréal, QC, Canada
| | - Jean-François Giroux
- Department of Biological Sciences, University of Quebec in Montreal, Montréal, QC, Canada
| | - An Tang
- Service of Radiology, University of Montreal Hospital (CHUM), Montréal, QC, Canada; Department of Radiology, Radio-Oncology and Nuclear Medicine, University of Montreal, Montréal, QC, Canada; Laboratory of Medical Image Analysis, University of Montreal Hospital Research Center (CRCHUM), Montréal, QC, Canada; Institute of Biomedical Engineering, University of Montreal, Montréal, QC, Canada
| | - Guy Cloutier
- Laboratory of Biorheology and Medical Ultrasonics, University of Montreal Hospital Research Center (CRCHUM), Montréal, QC, Canada; Department of Radiology, Radio-Oncology and Nuclear Medicine, University of Montreal, Montréal, QC, Canada; Institute of Biomedical Engineering, University of Montreal, Montréal, QC, Canada.
| |
Collapse
|
11
|
Demers G, Roy J, Machuca-Parra AI, Dashtehei Pour Z, Bairamian D, Daneault C, Rosiers CD, Ferreira G, Alquier T, Fulton S. Fish oil supplementation alleviates metabolic and anxiodepressive effects of diet-induced obesity and associated changes in brain lipid composition in mice. Int J Obes (Lond) 2020; 44:1936-1945. [PMID: 32546855 DOI: 10.1038/s41366-020-0623-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 05/01/2020] [Accepted: 05/22/2020] [Indexed: 01/03/2023]
Abstract
OBJECTIVE Obesity significantly elevates the odds of developing mood disorders. Chronic consumption of a saturated high-fat diet (HFD) elicits anxiodepressive behavior in a manner linked to metabolic dysfunction and neuroinflammation in mice. Dietary omega-3 polyunsaturated fatty acids (n-3 PUFA) can improve both metabolic and mood impairments by relieving inflammation. Despite these findings, the effects of n-3 PUFA supplementation on energy homeostasis, anxiodepressive behavior, brain lipid composition, and gliosis in the diet-induced obese state are unclear. METHODS Male C57Bl/6J mice were fed a saturated high-fat diet (HFD) or chow for 20 weeks. During the last 5 weeks mice received daily gavage ("supplementation") of fish oil (FO) enriched with equal amounts of docosahexaenoic (DHA) and eicosapentaenoic acid (EPA) or control corn oil. Food intake and body weight were measured throughout while additional metabolic parameters and anxiety- and despair-like behavior (elevated-plus maze, light-dark box, and forced swim tasks) were evaluated during the final week of supplementation. Forebrain lipid composition and markers of microglia activation and astrogliosis were assessed by gas chromatography-mass spectrometry and real-time PCR, respectively. RESULTS Five weeks of FO supplementation corrected glucose intolerance and attenuated hyperphagia in HFD-induced obese mice without affecting adipose mass. FO supplementation also defended against the anxiogenic and depressive-like effects of HFD. Brain lipids, particularly anti-inflammatory PUFA, were diminished by HFD, whereas FO restored levels beyond control values. Gene expression markers of brain reactive gliosis were supressed by FO. CONCLUSIONS Supplementing a saturated HFD with FO rich in EPA and DHA corrects glucose intolerance, inhibits food intake, suppresses anxiodepressive behaviors, enhances anti-inflammatory brain lipids, and dampens indices of brain gliosis in obese mice. Together, these findings support increasing dietary n-3 PUFA for the treatment of metabolic and mood disturbances associated with excess fat intake and obesity.
Collapse
Affiliation(s)
- Geneviève Demers
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, H2X 0A9, Canada.,Departments of Nutrition, Université de Montréal, MontrealQC, QC, H2X 0A9, Canada
| | - Jerome Roy
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, H2X 0A9, Canada
| | - Arturo Israel Machuca-Parra
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, H2X 0A9, Canada.,Departments of Medicine, Université de Montréal, Montréal, QC, Canada
| | - Zahra Dashtehei Pour
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, H2X 0A9, Canada.,Departments of Nutrition, Université de Montréal, MontrealQC, QC, H2X 0A9, Canada
| | - Diane Bairamian
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, H2X 0A9, Canada.,Departments of Nutrition, Université de Montréal, MontrealQC, QC, H2X 0A9, Canada
| | | | - Christine Des Rosiers
- Departments of Nutrition, Université de Montréal, MontrealQC, QC, H2X 0A9, Canada.,Montreal Heart Institute, Montréal, QC, Canada
| | - Guillaume Ferreira
- Nutrition and Integrative Neurobiology Unit, UMR1296 INRA - Université de Bordeaux, Bordeaux, France.,Food4BrainHealth France-Canada International Research Network, Bordeaux, France
| | - Thierry Alquier
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, H2X 0A9, Canada.,Departments of Medicine, Université de Montréal, Montréal, QC, Canada.,Food4BrainHealth France-Canada International Research Network, Bordeaux, France
| | - Stephanie Fulton
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, H2X 0A9, Canada. .,Departments of Nutrition, Université de Montréal, MontrealQC, QC, H2X 0A9, Canada. .,Food4BrainHealth France-Canada International Research Network, Bordeaux, France.
| | | |
Collapse
|
12
|
Abstract
The appropriate utilisation, storage and conversion of nutrients in peripheral tissues, referred to as nutrient partitioning, is a fundamental process to adapt to nutritional and metabolic challenges and is thus critical for the maintenance of a healthy energy balance. Alterations in this process during nutrient excess can have deleterious effects on glucose and lipid homeostasis and contribute to the development of obesity and type 2 diabetes. Nutrient partitioning is a complex integrated process under the control of hormonal and neural signals. Neural control relies on the capacity of the brain to sense circulating metabolic signals and mount adaptive neuroendocrine and autonomic responses. This review aims to discuss the hypothalamic neurocircuits and molecular mechanisms controlling nutrient partitioning and their potential contribution to metabolic maladaptation and disease.
Collapse
Affiliation(s)
- Romane Manceau
- Montréal Diabetes Research Center and Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 rue Saint-Denis, Montréal, QC, H2X 0A9, Canada
- Department of Neurosciences, Université de Montréal, Montréal, QC, Canada
| | - Danie Majeur
- Montréal Diabetes Research Center and Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 rue Saint-Denis, Montréal, QC, H2X 0A9, Canada
- Department of Neurosciences, Université de Montréal, Montréal, QC, Canada
| | - Thierry Alquier
- Montréal Diabetes Research Center and Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 rue Saint-Denis, Montréal, QC, H2X 0A9, Canada.
- Department of Medicine, Université de Montréal, Montréal, QC, Canada.
| |
Collapse
|
13
|
Moullé VS, Tremblay C, Castell AL, Vivot K, Ethier M, Fergusson G, Alquier T, Ghislain J, Poitout V. The autonomic nervous system regulates pancreatic β-cell proliferation in adult male rats. Am J Physiol Endocrinol Metab 2019; 317:E234-E243. [PMID: 31013146 PMCID: PMC6732465 DOI: 10.1152/ajpendo.00385.2018] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The pancreatic β-cell responds to changes in the nutrient environment to maintain glucose homeostasis by adapting its function and mass. Nutrients can act directly on the β-cell and also indirectly through the brain via autonomic nerves innervating islets. Despite the importance of the brain-islet axis in insulin secretion, relatively little is known regarding its involvement in β-cell proliferation. We previously demonstrated that prolonged infusions of nutrients in rats provoke a dramatic increase in β-cell proliferation in part because of the direct action of nutrients. Here, we addressed the contribution of the autonomic nervous system. In isolated islets, muscarinic stimulation increased, whereas adrenergic stimulation decreased, glucose-induced β-cell proliferation. Blocking α-adrenergic receptors reversed the effect of epinephrine on glucose + nonesterified fatty acids (NEFA)-induced β-cell proliferation, whereas activation of β-adrenergic receptors was without effect. Infusion of glucose + NEFA toward the brain stimulated β-cell proliferation, and this effect was abrogated following celiac vagotomy. The increase in β-cell proliferation following peripheral infusions of glucose + NEFA was not inhibited by vagotomy or atropine treatment but was blocked by coinfusion of epinephrine. We conclude that β-cell proliferation is stimulated by parasympathetic and inhibited by sympathetic signals. Whereas glucose + NEFA in the brain stimulates β-cell proliferation through the vagus nerve, β-cell proliferation in response to systemic nutrient excess does not involve parasympathetic signals but may be associated with decreased sympathetic tone.
Collapse
Affiliation(s)
- Valentine S Moullé
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
| | - Caroline Tremblay
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
| | - Anne-Laure Castell
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
| | - Kevin Vivot
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
| | - Mélanie Ethier
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
| | - Grace Fergusson
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
| | - Thierry Alquier
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
- Department of Medicine, University of Montreal , Quebec , Canada
| | - Julien Ghislain
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
| | - Vincent Poitout
- Montreal Diabetes Research Center , Montreal, Quebec , Canada
- CRCHUM, Montreal, Quebec , Canada
- Department of Medicine, University of Montreal , Quebec , Canada
| |
Collapse
|
14
|
Bouyakdan K, Martin H, Liénard F, Budry L, Taib B, Rodaros D, Chrétien C, Biron É, Husson Z, Cota D, Pénicaud L, Fulton S, Fioramonti X, Alquier T. The gliotransmitter ACBP controls feeding and energy homeostasis via the melanocortin system. J Clin Invest 2019; 129:2417-2430. [PMID: 30938715 PMCID: PMC6546475 DOI: 10.1172/jci123454] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Glial cells have emerged as key players in the central control of energy balance and etiology of obesity. Astrocytes play a central role in neural communication via the release of gliotransmitters. Acyl-CoA binding protein (ACBP)-derived endozepines are secreted peptides that modulate the GABAA receptor. In the hypothalamus, ACBP is enriched in arcuate nucleus (ARC) astrocytes, ependymocytes and tanycytes. Central administration of the endozepine octadecaneuropeptide (ODN) reduces feeding and improves glucose tolerance, yet the contribution of endogenous ACBP in energy homeostasis is unknown. We demonstrated that ACBP deletion in GFAP+ astrocytes, but not in Nkx2.1-lineage neural cells, promoted diet-induced hyperphagia and obesity in both male and female mice, an effect prevented by viral rescue of ACBP in ARC astrocytes. ACBP-astrocytes were observed in apposition with proopiomelanocortin (POMC) neurons and ODN selectively activated POMC neurons through the ODN-GPCR but not GABAA, and supressed feeding while increasing carbohydrate utilization via the melanocortin system. Similarly, ACBP overexpression in ARC astrocytes reduced feeding and weight gain. Finally, the ODN-GPCR agonist decreased feeding and promoted weight loss in ob/ob mice. These findings uncover ACBP as an ARC gliopeptide playing a key role in energy balance control and exerting strong anorectic effects via the central melanocortin system.
Collapse
Affiliation(s)
- Khalil Bouyakdan
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine, Pathology and Cell Biology, Biochemistry, Neurosciences, and Nutrition, Université de Montréal, Montreal, Quebec, Canada
| | - Hugo Martin
- Université de Bordeaux, INRA, NutriNeuro, Bordeaux, France
- Bordeaux INP, NutriNeuro, Talence, France
| | - Fabienne Liénard
- Centre des Sciences du Goût et de l’Alimentation, UMR 6265 CNRS, 1324 INRA, Université de Bourgogne Franche-Comté, Dijon, France
| | - Lionel Budry
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine, Pathology and Cell Biology, Biochemistry, Neurosciences, and Nutrition, Université de Montréal, Montreal, Quebec, Canada
| | - Bouchra Taib
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine, Pathology and Cell Biology, Biochemistry, Neurosciences, and Nutrition, Université de Montréal, Montreal, Quebec, Canada
| | - Demetra Rodaros
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine, Pathology and Cell Biology, Biochemistry, Neurosciences, and Nutrition, Université de Montréal, Montreal, Quebec, Canada
| | - Chloé Chrétien
- Centre des Sciences du Goût et de l’Alimentation, UMR 6265 CNRS, 1324 INRA, Université de Bourgogne Franche-Comté, Dijon, France
| | - Éric Biron
- Faculty of Pharmacy, Université Laval and Laboratory of Medicinal Chemistry, Centre de Recherche du Centre Hospitalier Universitaire de Québec (CRCHUQ), Quebec, Quebec, Canada
| | - Zoé Husson
- Université de Bordeaux, INRA, NutriNeuro, Bordeaux, France
- Bordeaux INP, NutriNeuro, Talence, France
- INSERM, Université de Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, Bordeaux, France
| | - Daniela Cota
- INSERM, Université de Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, Bordeaux, France
| | - Luc Pénicaud
- Centre des Sciences du Goût et de l’Alimentation, UMR 6265 CNRS, 1324 INRA, Université de Bourgogne Franche-Comté, Dijon, France
- Stromalab, CNRS ERL 5311, Université de Toulouse, Université Paul Sabatier, Toulouse, France
| | - Stephanie Fulton
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine, Pathology and Cell Biology, Biochemistry, Neurosciences, and Nutrition, Université de Montréal, Montreal, Quebec, Canada
| | - Xavier Fioramonti
- Université de Bordeaux, INRA, NutriNeuro, Bordeaux, France
- Bordeaux INP, NutriNeuro, Talence, France
- Centre des Sciences du Goût et de l’Alimentation, UMR 6265 CNRS, 1324 INRA, Université de Bourgogne Franche-Comté, Dijon, France
| | - Thierry Alquier
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal Diabetes Research Center, and Departments of Medicine, Pathology and Cell Biology, Biochemistry, Neurosciences, and Nutrition, Université de Montréal, Montreal, Quebec, Canada
| |
Collapse
|
15
|
Décarie-Spain L, Sharma S, Hryhorczuk C, Issa-Garcia V, Barker PA, Arbour N, Alquier T, Fulton S. Nucleus accumbens inflammation mediates anxiodepressive behavior and compulsive sucrose seeking elicited by saturated dietary fat. Mol Metab 2018; 10:1-13. [PMID: 29454579 PMCID: PMC5985233 DOI: 10.1016/j.molmet.2018.01.018] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 01/09/2018] [Accepted: 01/20/2018] [Indexed: 12/23/2022] Open
Abstract
OBJECTIVE The incidence of depression is significantly compounded by obesity. Obesity arising from excessive intake of high-fat food provokes anxiodepressive behavior and elicits molecular adaptations in the nucleus accumbens (NAc), a region well-implicated in the hedonic deficits associated with depression and in the control of food-motivated behavior. To determine the etiology of diet-induced depression, we studied the impact of different dietary lipids on anxiodepressive behavior and metabolic and immune outcomes and the contribution of NAc immune activity. METHODS Adult C57Bl/6 mice were subjected to isocaloric high-fat/high-sucrose diets (HFD), enriched in either saturated or monounsaturated fat, or a control low-fat diet (LFD). Metabolic responses, anxiodepressive behavior, and plasma and NAc inflammatory markers were assessed after 12 weeks. In separate experiments, an adenoviral construct inhibiting IKKβ, an upstream component of the nuclear factor kappa-b (NFkB) pathway, was a priori injected into the NAc. RESULTS Both HFDs resulted in obesity and hyperleptinemia; however, the saturated HFD uniquely triggered anxiety-like behavior, behavioral despair, hyperinsulinemia, glucose intolerance, peripheral inflammation, and multiple pro-inflammatory signs in the NAc, including reactive gliosis, increased expression of cytokines, antigen-presenting markers and NFкB transcriptional activity. Selective NAc IKKβ inhibition reversed the upregulated expression of inflammatory markers, prevented anxiodepressive behavior and blunted compulsive sucrose-seeking in mice fed the saturated HFD. CONCLUSIONS Metabolic inflammation and NFкB-mediated neuroinflammatory responses in the NAc contribute to the expression of anxiodepressive behavior and heightened food cravings caused by a diet high in saturated fat and sugar.
Collapse
Affiliation(s)
- Léa Décarie-Spain
- Centre de Recherche du CHUM, Université de Montréal, Quebec, Canada; Montreal Diabetes Research Centre, Université de Montréal, Quebec, Canada; Department of Neuroscience, Université de Montréal, Quebec, Canada
| | - Sandeep Sharma
- Centre de Recherche du CHUM, Université de Montréal, Quebec, Canada; Montreal Diabetes Research Centre, Université de Montréal, Quebec, Canada; Department of Nutrition, Université de Montréal, Quebec, Canada
| | - Cécile Hryhorczuk
- Centre de Recherche du CHUM, Université de Montréal, Quebec, Canada; Montreal Diabetes Research Centre, Université de Montréal, Quebec, Canada
| | - Victor Issa-Garcia
- Centre de Recherche du CHUM, Université de Montréal, Quebec, Canada; Montreal Diabetes Research Centre, Université de Montréal, Quebec, Canada
| | - Philip A Barker
- Department of Biology, University of British Columbia, BC, Canada
| | - Nathalie Arbour
- Centre de Recherche du CHUM, Université de Montréal, Quebec, Canada; Department of Neuroscience, Université de Montréal, Quebec, Canada
| | - Thierry Alquier
- Centre de Recherche du CHUM, Université de Montréal, Quebec, Canada; Montreal Diabetes Research Centre, Université de Montréal, Quebec, Canada; Department of Medicine, Université de Montréal, Quebec, Canada
| | - Stephanie Fulton
- Centre de Recherche du CHUM, Université de Montréal, Quebec, Canada; Montreal Diabetes Research Centre, Université de Montréal, Quebec, Canada; Department of Nutrition, Université de Montréal, Quebec, Canada.
| |
Collapse
|
16
|
Abstract
Mice are the most commonly used species in preclinical research on the pathophysiology of metabolic diseases. Although they are extremely useful for identifying pathways, mechanisms and genes regulating glucose and energy homeostasis, the specificities of the various mouse models and methodologies used to investigate a metabolic phenotype can have a profound impact on experimental results and their interpretation. This review aims to: (1) describe the most commonly used experimental tests to assess glucose and energy homeostasis in mice; (2) provide some guidelines regarding the design, analysis and interpretation of these tests, as well as for studies using genetic models; and (3) identify important caveats and confounding factors that must be taken into account in the interpretation of findings.
Collapse
Affiliation(s)
- Thierry Alquier
- Montreal Diabetes Research Center and Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 rue Saint-Denis, Office R08-418, Montreal, QC, H2X 0A9, Canada.
- Department of Medicine, Université de Montréal, Montreal, QC, Canada.
| | - Vincent Poitout
- Montreal Diabetes Research Center and Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 rue Saint-Denis, Office R08-418, Montreal, QC, H2X 0A9, Canada
- Department of Medicine, Université de Montréal, Montreal, QC, Canada
| |
Collapse
|
17
|
Hryhorczuk C, Sheng Z, Décarie-Spain L, Giguère N, Ducrot C, Trudeau LÉ, Routh VH, Alquier T, Fulton S. Oleic Acid in the Ventral Tegmental Area Inhibits Feeding, Food Reward, and Dopamine Tone. Neuropsychopharmacology 2018; 43:607-616. [PMID: 28857071 PMCID: PMC5770761 DOI: 10.1038/npp.2017.203] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Revised: 08/23/2017] [Accepted: 08/28/2017] [Indexed: 12/16/2022]
Abstract
Long-chain fatty acids (FAs) act centrally to decrease food intake and hepatic glucose production and alter hypothalamic neuronal activity in a manner that depends on FA type and cellular transport proteins. However, it is not known whether FAs are sensed by ventral tegmental area (VTA) dopamine (DA) neurons to control food-motivated behavior and DA neurotransmission. We investigated the impact of the monounsaturated FA oleate in the VTA on feeding, locomotion, food reward, and DA neuronal activity and DA neuron expression of FA-handling proteins and FA uptake. A single intra-VTA injection of oleate, but not of the saturated FA palmitate, decreased food intake and increased locomotor activity. Furthermore, intra-VTA oleate blunted the rewarding effects of high-fat/sugar food in an operant task and inhibited DA neuronal firing. Using sorted DA neuron preparations from TH-eGFP mice we found that DA neurons express FA transporter and binding proteins, and are capable of intracellular transport of long-chain FA. Finally, we demonstrate that a transporter blocker attenuates FA uptake into DA neurons and blocks the effects of intra-VTA oleate to decrease food-seeking and DA neuronal activity. Together, these results suggest that DA neurons detect FA and that oleate has actions in the VTA to suppress DA neuronal activity and food seeking following cellular incorporation. These findings highlight the capacity of DA neurons to act as metabolic sensors by responding not only to hormones but also to FA nutrient signals to modulate food-directed behavior.
Collapse
Affiliation(s)
- Cecile Hryhorczuk
- CRCHUM and Montreal Diabetes Research Center, Montréal, QC, Canada,Department of Physiology, Université de Montréal, Montréal, QC, Canada
| | - Zhenyu Sheng
- Rutgers New Jersey Medical School, Department of Pharmacology, Physiology and Neuroscience, Rutgers University, Newark, NJ, USA
| | - Léa Décarie-Spain
- CRCHUM and Montreal Diabetes Research Center, Montréal, QC, Canada,Department of Neurosciences, Université de Montréal, Montréal, QC, Canada
| | - Nicolas Giguère
- Department of Pharmacology, Université de Montréal, Montréal, QC, Canada
| | - Charles Ducrot
- Department of Pharmacology, Université de Montréal, Montréal, QC, Canada
| | - Louis-Éric Trudeau
- Department of Pharmacology, Université de Montréal, Montréal, QC, Canada
| | - Vanessa H Routh
- Rutgers New Jersey Medical School, Department of Pharmacology, Physiology and Neuroscience, Rutgers University, Newark, NJ, USA
| | - Thierry Alquier
- CRCHUM and Montreal Diabetes Research Center, Montréal, QC, Canada,Department of Medicine, Université de Montréal, Montréal, QC, Canada
| | - Stephanie Fulton
- CRCHUM and Montreal Diabetes Research Center, Montréal, QC, Canada,Department of Nutrition, Université de Montréal, Montréal, QC, Canada,CRCHUM and Montreal Diabetes Research Center, 900 rue Saint-Denis, Office 8-428, Montreal, QC, Canada H2X 0A9, Tel: +514.890.8000 × 23602, E-mail:
| |
Collapse
|
18
|
Hryhorczuk C, Décarie-Spain L, Sharma S, Daneault C, Rosiers CD, Alquier T, Fulton S. Saturated high-fat feeding independent of obesity alters hypothalamus-pituitary-adrenal axis function but not anxiety-like behaviour. Psychoneuroendocrinology 2017. [PMID: 28623763 DOI: 10.1016/j.psyneuen.2017.06.002] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Overconsumption of dietary fat can elicit impairments in emotional processes and the response to stress. While excess dietary lipids have been shown to alter hypothalamus-pituitary-adrenal (HPA) axis function and promote anxiety-like behaviour, it is not known if such changes rely on elevated body weight and if these effects are specific to the type of dietary fat. The objective of this study was to investigate the effect of a saturated and a monounsaturated high-fat diet (HFD) on HPA axis function and anxiety-like behaviour in rats. Biochemical, metabolic and behavioural responses were evaluated following eight weeks on one of three diets: (1) a monounsaturated HFD (50%kcal olive oil), (2) a saturated HFD (50%kcal palm oil), or (3) a control low-fat diet. Weight gain was similar across the three diets while visceral fat mass was elevated by the two HFDs. The saturated HFD had specific actions to increase peak plasma levels of corticosterone and tumour-necrosis-factor-alpha and suppress mRNA expression of glucocorticoid and mineralocorticoid receptors, corticotropin-releasing hormone and 11β-hydroxysteroid dehydrogenase-1 in the paraventricular nucleus of the hypothalamus. Both HFDs enhanced the corticosterone-suppressing response to dexamethasone administration without affecting the physiological response to a restraint stress and failed to increase anxiety-like behaviour as measured in the elevated-plus maze and open field tests. These findings demonstrate that prolonged intake of saturated fat, without added weight gain, increases CORT and modulates central HPA feedback processes. That saturated HFD failed to affect anxiety-like behaviour can suggest that the anxiogenic effects of prolonged high-fat feeding may rely on more pronounced metabolic dysfunction.
Collapse
Affiliation(s)
- Cecile Hryhorczuk
- CRCHUM and Montreal Diabetes Research Center, Montreal, QC, Canada; Departments of Physiology, Université de Montréal, QC, Canada
| | - Léa Décarie-Spain
- CRCHUM and Montreal Diabetes Research Center, Montreal, QC, Canada; Departments of Neuroscience, Université de Montréal, QC, Canada
| | - Sandeep Sharma
- CRCHUM and Montreal Diabetes Research Center, Montreal, QC, Canada
| | | | - Christine Des Rosiers
- Departments of Nutrition, Université de Montréal, QC, Canada; Montreal Heart Institute, Montreal, QC, Canada
| | - Thierry Alquier
- CRCHUM and Montreal Diabetes Research Center, Montreal, QC, Canada; Departments of Medicine, Université de Montréal, QC, Canada.
| | - Stephanie Fulton
- CRCHUM and Montreal Diabetes Research Center, Montreal, QC, Canada; Departments of Nutrition, Université de Montréal, QC, Canada
| |
Collapse
|
19
|
Ghosh A, Abdo S, Zhao S, Wu CH, Shi Y, Lo CS, Chenier I, Alquier T, Filep JG, Ingelfinger JR, Zhang SL, Chan JSD. Insulin Inhibits Nrf2 Gene Expression via Heterogeneous Nuclear Ribonucleoprotein F/K in Diabetic Mice. Endocrinology 2017; 158:903-919. [PMID: 28324005 PMCID: PMC5460794 DOI: 10.1210/en.2016-1576] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 01/17/2017] [Indexed: 11/19/2022]
Abstract
Oxidative stress induces endogenous antioxidants via nuclear factor erythroid 2-related factor 2 (Nrf2), potentially preventing tissue injury. We investigated whether insulin affects renal Nrf2 expression in type 1 diabetes (T1D) and studied its underlying mechanism. Insulin normalized hyperglycemia, hypertension, oxidative stress, and renal injury; inhibited renal Nrf2 and angiotensinogen (Agt) gene expression; and upregulated heterogeneous nuclear ribonucleoprotein F and K (hnRNP F and hnRNP K) expression in Akita mice with T1D. In immortalized rat renal proximal tubular cells, insulin suppressed Nrf2 and Agt but stimulated hnRNP F and hnRNP K gene transcription in high glucose via p44/42 mitogen-activated protein kinase signaling. Transfection with small interfering RNAs of p44/42 MAPK, hnRNP F, or hnRNP K blocked insulin inhibition of Nrf2 gene transcription. Insulin curbed Nrf2 promoter activity via a specific DNA-responsive element that binds hnRNP F/K, and hnRNP F/K overexpression curtailed Nrf2 promoter activity. In hyperinsulinemic-euglycemic mice, renal Nrf2 and Agt expression was downregulated, whereas hnRNP F/K expression was upregulated. Thus, the beneficial actions of insulin in diabetic nephropathy appear to be mediated, in part, by suppressing renal Nrf2 and Agt gene transcription and preventing Nrf2 stimulation of Agt expression via hnRNP F/K. These findings identify hnRNP F/K and Nrf2 as potential therapeutic targets in diabetes.
Collapse
Affiliation(s)
- Anindya Ghosh
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Shaaban Abdo
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Shuiling Zhao
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Chin-Han Wu
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Yixuan Shi
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Chao-Sheng Lo
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Isabelle Chenier
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Thierry Alquier
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Janos G Filep
- Department of Pathology and Cell Biology, Université de Montréal and Centre de recherche, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
| | - Julie R Ingelfinger
- Pediatric Nephrology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Shao-Ling Zhang
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - John S D Chan
- Department of Medicine, Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| |
Collapse
|
20
|
Fisette A, Tobin S, Décarie-Spain L, Bouyakdan K, Peyot ML, Madiraju S, Prentki M, Fulton S, Alquier T. α/β-Hydrolase Domain 6 in the Ventromedial Hypothalamus Controls Energy Metabolism Flexibility. Cell Rep 2016; 17:1217-1226. [DOI: 10.1016/j.celrep.2016.10.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 08/30/2016] [Accepted: 09/30/2016] [Indexed: 01/24/2023] Open
|
21
|
Auguste S, Fisette A, Fernandes MF, Hryhorczuk C, Poitout V, Alquier T, Fulton S. Central Agonism of GPR120 Acutely Inhibits Food Intake and Food Reward and Chronically Suppresses Anxiety-Like Behavior in Mice. Int J Neuropsychopharmacol 2016; 19:pyw014. [PMID: 26888796 PMCID: PMC4966276 DOI: 10.1093/ijnp/pyw014] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 02/09/2016] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND GPR120 (FFAR4) is a G-protein coupled receptor implicated in the development of obesity and the antiinflammatory and insulin-sensitizing effects of omega-3 (ω-3) polyunsaturated fatty acids. Increasing central ω-3 polyunsaturated fatty acid levels has been shown to have both anorectic and anxiolytic actions. Despite the strong clinical interest in GPR120, its role in the brain is largely unknown, and thus we sought to determine the impact of central GPR120 pharmacological activation on energy balance, food reward, and anxiety-like behavior. METHODS Male C57Bl/6 mice with intracerebroventricular cannulae received a single injection (0.1 or 1 µM) or continuous 2-week infusion (1 µM/d; mini-pump) of a GPR120 agonist or vehicle. Free-feeding intake, operant lever-pressing for palatable food, energy expenditure (indirect calorimetry), and body weight were measured. GPR120 mRNA expression was measured in pertinent brain areas. Anxiety-like behavior was assessed in the elevated-plus maze and open field test. RESULTS GPR120 agonist injections substantially reduced chow intake during 4 hours postinjection, suppressed the rewarding effects of high-fat/-sugar food, and blunted approach-avoidance behavior in the open field. Conversely, prolonged central GPR120 agonist infusions reduced anxiety-like behavior in the elevated-plus maze and open field, yet failed to affect free-feeding intake, energy expenditure, and body weight on a high-fat diet. CONCLUSION Acute reductions in food intake and food reward suggest that GPR120 could mediate the effects of central ω-3 polyunsaturated fatty acids to inhibit appetite. The anxiolytic effect elicited by GPR120 agonist infusions favors the testing of compounds that can enter the brain to activate GPR120 for the mitigation of anxiety.
Collapse
Affiliation(s)
- Stéphanie Auguste
- CRCHUM & Montreal Diabetes Research Center (Drs Auguste, Fisette, and Fernandes, Ms Hryhorczuk, and Drs Poitout, Alquier, and Fulton); Department of Nutrition (Drs Auguste, Fisette, and Fulton), Department of Physiology (Dr Fernandes and Ms Hryhorczuk), and Department of Medicine (Drs Poitout and Alquier), Faculty of Medicine, Université de Montréal, QC, Canada.
| | - Alexandre Fisette
- CRCHUM & Montreal Diabetes Research Center (Drs Auguste, Fisette, and Fernandes, Ms Hryhorczuk, and Drs Poitout, Alquier, and Fulton); Department of Nutrition (Drs Auguste, Fisette, and Fulton), Department of Physiology (Dr Fernandes and Ms Hryhorczuk), and Department of Medicine (Drs Poitout and Alquier), Faculty of Medicine, Université de Montréal, QC, Canada
| | - Maria F Fernandes
- CRCHUM & Montreal Diabetes Research Center (Drs Auguste, Fisette, and Fernandes, Ms Hryhorczuk, and Drs Poitout, Alquier, and Fulton); Department of Nutrition (Drs Auguste, Fisette, and Fulton), Department of Physiology (Dr Fernandes and Ms Hryhorczuk), and Department of Medicine (Drs Poitout and Alquier), Faculty of Medicine, Université de Montréal, QC, Canada
| | - Cécile Hryhorczuk
- CRCHUM & Montreal Diabetes Research Center (Drs Auguste, Fisette, and Fernandes, Ms Hryhorczuk, and Drs Poitout, Alquier, and Fulton); Department of Nutrition (Drs Auguste, Fisette, and Fulton), Department of Physiology (Dr Fernandes and Ms Hryhorczuk), and Department of Medicine (Drs Poitout and Alquier), Faculty of Medicine, Université de Montréal, QC, Canada
| | - Vincent Poitout
- CRCHUM & Montreal Diabetes Research Center (Drs Auguste, Fisette, and Fernandes, Ms Hryhorczuk, and Drs Poitout, Alquier, and Fulton); Department of Nutrition (Drs Auguste, Fisette, and Fulton), Department of Physiology (Dr Fernandes and Ms Hryhorczuk), and Department of Medicine (Drs Poitout and Alquier), Faculty of Medicine, Université de Montréal, QC, Canada
| | - Thierry Alquier
- CRCHUM & Montreal Diabetes Research Center (Drs Auguste, Fisette, and Fernandes, Ms Hryhorczuk, and Drs Poitout, Alquier, and Fulton); Department of Nutrition (Drs Auguste, Fisette, and Fulton), Department of Physiology (Dr Fernandes and Ms Hryhorczuk), and Department of Medicine (Drs Poitout and Alquier), Faculty of Medicine, Université de Montréal, QC, Canada
| | - Stephanie Fulton
- CRCHUM & Montreal Diabetes Research Center (Drs Auguste, Fisette, and Fernandes, Ms Hryhorczuk, and Drs Poitout, Alquier, and Fulton); Department of Nutrition (Drs Auguste, Fisette, and Fulton), Department of Physiology (Dr Fernandes and Ms Hryhorczuk), and Department of Medicine (Drs Poitout and Alquier), Faculty of Medicine, Université de Montréal, QC, Canada
| |
Collapse
|
22
|
Budry L, Bouyakdan K, Tobin S, Rodaros D, Marcher AB, Mandrup S, Fulton S, Alquier T. DBI/ACBP loss-of-function does not affect anxiety-like behaviour but reduces anxiolytic responses to diazepam in mice. Behav Brain Res 2016; 313:201-207. [PMID: 27363924 DOI: 10.1016/j.bbr.2016.06.052] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Revised: 06/13/2016] [Accepted: 06/14/2016] [Indexed: 11/18/2022]
Abstract
Diazepam is well known for its anxiolytic properties, which are mediated via activation of the GABAA receptor. Diazepam Binding Inhibitor (DBI), also called acyl-CoA binding protein (ACBP), is a ubiquitously expressed protein originally identified based on its ability to displace diazepam from its binding site on the GABAA receptor. Central administration of ACBP or its cleaved fragment, commonly referred to as endozepines, induces proconflict and anxiety-like behaviour in rodents. For this reason, ACBP is known as an anxiogenic peptide. However, the role of endogenous ACBP in anxiety-like behaviour and anxiolytic responses to diazepam has not been investigated. To address this question, we assessed anxiety behaviour and anxiolytic responses to diazepam in two complementary loss-of-function mouse models including astrocyte-specific ACBP KO (ACBP(GFAP) KO) and whole-body KO (ACBP KO) mice. Male and female ACBP(GFAP) KO and ACBP KO mice do not show significant changes in anxiety-like behaviour compared to control littermates during elevated plus maze (EPM) and open field (OF) tests. Surprisingly, ACBP(GFAP) KO and ACBP KO mice were unresponsive to the anxiolytic effect of a low dose of diazepam during EPM tests. In conclusion, our experiments using genetic ACBP loss-of-function models suggest that endozepines deficiency does not affect anxiety-like behaviour in mice and impairs the anxiolytic action of diazepam.
Collapse
Affiliation(s)
- Lionel Budry
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), University of Montreal, Montreal, QC, H3T 1J4, Canada; Department of Medicine, University of Montreal, Montreal, QC, H3T 1J4, Canada
| | - Khalil Bouyakdan
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), University of Montreal, Montreal, QC, H3T 1J4, Canada; Department of Biochemistry, University of Montreal, Montreal, QC, H3T 1J4, Canada
| | - Stephanie Tobin
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), University of Montreal, Montreal, QC, H3T 1J4, Canada; Department of Medicine, University of Montreal, Montreal, QC, H3T 1J4, Canada
| | - Demetra Rodaros
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), University of Montreal, Montreal, QC, H3T 1J4, Canada
| | - Ann-Britt Marcher
- Departments of Biochemistry and Molecular Biology, University of Southern Denmark, DK-5230 Odense M, Denmark
| | - Susanne Mandrup
- Departments of Biochemistry and Molecular Biology, University of Southern Denmark, DK-5230 Odense M, Denmark
| | - Stephanie Fulton
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), University of Montreal, Montreal, QC, H3T 1J4, Canada; Department of Nutrition, University of Montreal, Montreal, QC, H3T 1J4, Canada
| | - Thierry Alquier
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), University of Montreal, Montreal, QC, H3T 1J4, Canada; Department of Medicine, University of Montreal, Montreal, QC, H3T 1J4, Canada; Department of Biochemistry, University of Montreal, Montreal, QC, H3T 1J4, Canada; Departments of Pathology and Cell Biology, University of Montreal, Montreal, QC, H3T 1J4, Canada.
| |
Collapse
|
23
|
Hryhorczuk C, Florea M, Rodaros D, Poirier I, Daneault C, Des Rosiers C, Arvanitogiannis A, Alquier T, Fulton S. Dampened Mesolimbic Dopamine Function and Signaling by Saturated but not Monounsaturated Dietary Lipids. Neuropsychopharmacology 2016; 41:811-21. [PMID: 26171719 PMCID: PMC4707827 DOI: 10.1038/npp.2015.207] [Citation(s) in RCA: 89] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 06/02/2015] [Accepted: 06/10/2015] [Indexed: 01/04/2023]
Abstract
Overconsumption of dietary fat is increasingly linked with motivational and emotional impairments. Human and animal studies demonstrate associations between obesity and blunted reward function at the behavioral and neural level, but it is unclear to what degree such changes are a consequence of an obese state and whether they are contingent on dietary lipid class. We sought to determine the impact of prolonged ad libitum intake of diets rich in saturated or monounsaturated fat, separate from metabolic signals associated with increased adiposity, on dopamine (DA)-dependent behaviors and to identify pertinent signaling changes in the nucleus accumbens (NAc). Male rats fed a saturated (palm oil), but not an isocaloric monounsaturated (olive oil), high-fat diet exhibited decreased sensitivity to the rewarding (place preference) and locomotor-sensitizing effects of amphetamine as compared with low-fat diet controls. Blunted amphetamine action by saturated high-fat feeding was entirely independent of caloric intake, weight gain, and plasma levels of leptin, insulin, and glucose and was accompanied by biochemical and behavioral evidence of reduced D1R signaling in the NAc. Saturated high-fat feeding was also tied to protein markers of increased AMPA receptor-mediated plasticity and decreased DA transporter expression in the NAc but not to alterations in DA turnover and biosynthesis. Collectively, the results suggest that intake of saturated lipids can suppress DA signaling apart from increases in body weight and adiposity-related signals known to affect mesolimbic DA function, in part by diminishing D1 receptor signaling, and that equivalent intake of monounsaturated dietary fat protects against such changes.
Collapse
Affiliation(s)
- Cecile Hryhorczuk
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, Canada,Department of Physiology, Université de Montréal, Montreal, QC, Canada
| | - Marc Florea
- Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC, Canada
| | - Demetra Rodaros
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, Canada
| | - Isabelle Poirier
- Department of Nutrition, Université de Montréal, Montreal, QC, Canada
| | | | - Christine Des Rosiers
- Department of Nutrition, Université de Montréal, Montreal, QC, Canada,Montreal Heart Institute, Montreal, QC, Canada
| | | | - Thierry Alquier
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, Canada,Department of Medicine, Université de Montréal, Montreal, QC, Canada
| | - Stephanie Fulton
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Montreal, QC, Canada,Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC, Canada,Department of Nutrition, Université de Montréal, Montreal, QC, Canada,CRCHUM and Montreal Diabetes Research Center, 900 rue Saint-Denis, Office 8-428, Montreal, QC H2X 0A9, Canada, Tel: +1 514 890 8000, ex 23602, E-mail:
| |
Collapse
|
24
|
Oropeza D, Jouvet N, Budry L, Campbell JE, Bouyakdan K, Lacombe J, Perron G, Bergeron V, Neuman JC, Brar HK, Fenske RJ, Meunier C, Sczelecki S, Kimple ME, Drucker DJ, Screaton RA, Poitout V, Ferron M, Alquier T, Estall JL. Phenotypic Characterization of MIP-CreERT1Lphi Mice With Transgene-Driven Islet Expression of Human Growth Hormone. Diabetes 2015; 64:3798-807. [PMID: 26153246 PMCID: PMC4613972 DOI: 10.2337/db15-0272] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Accepted: 06/24/2015] [Indexed: 01/17/2023]
Abstract
There is growing concern over confounding artifacts associated with β-cell-specific Cre-recombinase transgenic models, raising questions about their general usefulness in research. The inducible β-cell-specific transgenic (MIP-CreERT(1Lphi)) mouse was designed to circumvent many of these issues, and we investigated whether this tool effectively addressed concerns of ectopic expression and disruption of glucose metabolism. Recombinase activity was absent from the central nervous system using a reporter line and high-resolution microscopy. Despite increased pancreatic insulin content, MIP-CreERT mice on a chow diet exhibited normal ambient glycemia, glucose tolerance and insulin sensitivity, and appropriate insulin secretion in response to glucose in vivo and in vitro. However, MIP-CreERT mice on different genetic backgrounds were protected from high-fat/ streptozotocin (STZ)-induced hyperglycemia that was accompanied by increased insulin content and islet density. Ectopic human growth hormone (hGH) was highly expressed in MIP-CreERT islets independent of tamoxifen administration. Circulating insulin levels remained similar to wild-type controls, whereas STZ-associated increases in α-cell number and serum glucagon were significantly blunted in MIP-CreERT(1Lphi) mice, possibly due to paracrine effects of hGH-induced serotonin expression. These studies reveal important new insight into the strengths and limitations of the MIP-CreERT mouse line for β-cell research.
Collapse
Affiliation(s)
- Daniel Oropeza
- Institut de recherches cliniques de Montréal, Montreal, QC, Canada Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada
| | - Nathalie Jouvet
- Institut de recherches cliniques de Montréal, Montreal, QC, Canada Division of Experimental Medicine, McGill University, Montreal, QC, Canada
| | - Lionel Budry
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
| | - Jonathan E Campbell
- Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
| | - Khalil Bouyakdan
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada Département de Médecine, Université de Montréal, Montreal, QC, Canada
| | - Julie Lacombe
- Institut de recherches cliniques de Montréal, Montreal, QC, Canada
| | - Gabrielle Perron
- Institut de recherches cliniques de Montréal, Montreal, QC, Canada Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada
| | - Valerie Bergeron
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada Département de Médecine, Université de Montréal, Montreal, QC, Canada
| | - Joshua C Neuman
- Department of Medicine and Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison, Madison, WI
| | - Harpreet K Brar
- Department of Medicine and Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison, Madison, WI
| | - Rachel J Fenske
- Department of Medicine and Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison, Madison, WI
| | - Clemence Meunier
- Institut de recherches cliniques de Montréal, Montreal, QC, Canada
| | - Sarah Sczelecki
- Division of Experimental Medicine, McGill University, Montreal, QC, Canada
| | - Michelle E Kimple
- Department of Medicine and Interdisciplinary Graduate Program in Nutritional Sciences, University of Wisconsin-Madison, Madison, WI
| | - Daniel J Drucker
- Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
| | - Robert A Screaton
- Department of Cellular and Molecular Medicine, Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada
| | - Vincent Poitout
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada Département de Médecine, Université de Montréal, Montreal, QC, Canada
| | - Mathieu Ferron
- Institut de recherches cliniques de Montréal, Montreal, QC, Canada Division of Experimental Medicine, McGill University, Montreal, QC, Canada Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
| | - Thierry Alquier
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada Département de Médecine, Université de Montréal, Montreal, QC, Canada
| | - Jennifer L Estall
- Institut de recherches cliniques de Montréal, Montreal, QC, Canada Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada Division of Experimental Medicine, McGill University, Montreal, QC, Canada Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada Département de Médecine, Université de Montréal, Montreal, QC, Canada
| |
Collapse
|
25
|
Fernandes MFA, Matthys D, Hryhorczuk C, Sharma S, Mogra S, Alquier T, Fulton S. Leptin Suppresses the Rewarding Effects of Running via STAT3 Signaling in Dopamine Neurons. Cell Metab 2015; 22:741-9. [PMID: 26341832 DOI: 10.1016/j.cmet.2015.08.003] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Revised: 06/12/2015] [Accepted: 08/05/2015] [Indexed: 01/29/2023]
Abstract
The adipose hormone leptin potently influences physical activity. Leptin can decrease locomotion and running, yet the mechanisms involved and the influence of leptin on the rewarding effects of running ("runner's high") are unknown. Leptin receptor (LepR) signaling involves activation of signal transducer and activator of transcription-3 (STAT3), including in dopamine neurons of the ventral tegmental area (VTA) that are essential for reward-relevant behavior. We found that mice lacking STAT3 in dopamine neurons exhibit greater voluntary running, an effect reversed by viral-mediated STAT3 restoration. STAT3 deletion increased the rewarding effects of running whereas intra-VTA leptin blocked it in a STAT3-dependent manner. Finally, STAT3 loss-of-function reduced mesolimbic dopamine overflow and function. Findings suggest that leptin influences the motivational effects of running via LepR-STAT3 modulation of dopamine tone. Falling leptin is hypothesized to increase stamina and the rewarding effects of running as an adaptive means to enhance the pursuit and procurement of food.
Collapse
Affiliation(s)
- Maria Fernanda A Fernandes
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Université de Montreal, QC H2X 0A9, Canada; Department of Physiology, Université de Montreal, QC H2X 0A9, Canada
| | - Dominique Matthys
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Université de Montreal, QC H2X 0A9, Canada; Department of Neuroscience, Université de Montreal, QC H2X 0A9, Canada
| | - Cécile Hryhorczuk
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Université de Montreal, QC H2X 0A9, Canada; Department of Physiology, Université de Montreal, QC H2X 0A9, Canada
| | - Sandeep Sharma
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Université de Montreal, QC H2X 0A9, Canada; Department of Nutrition, Université de Montreal, QC H2X 0A9, Canada
| | - Shabana Mogra
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Université de Montreal, QC H2X 0A9, Canada
| | - Thierry Alquier
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Université de Montreal, QC H2X 0A9, Canada; Department of Medicine, Université de Montreal, QC H2X 0A9, Canada
| | - Stephanie Fulton
- Centre de Recherche du CHUM and Montreal Diabetes Research Center, Université de Montreal, QC H2X 0A9, Canada; Department of Nutrition, Université de Montreal, QC H2X 0A9, Canada; Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC H4B 1R6, Canada.
| |
Collapse
|
26
|
Affiliation(s)
- Alexandre Fisette
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Canada ; Department of Nutrition, University of Montreal, Montreal, QC H3T 1J4, Canada
| | - Thierry Alquier
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Canada ; Department of Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada ; Department of Biochemistry, University of Montreal, Montreal, QC H3T 1J4, Canada ; Department of Pathology and Cell Biology, University of Montreal, Montreal, QC H3T 1J4, Canada
| |
Collapse
|
27
|
Oropeza D, Jouvet N, Bouyakdan K, Perron G, Ringuette LJ, Philipson LH, Kiss RS, Poitout V, Alquier T, Estall JL. PGC-1 coactivators in β-cells regulate lipid metabolism and are essential for insulin secretion coupled to fatty acids. Mol Metab 2015; 4:811-22. [PMID: 26629405 PMCID: PMC4632114 DOI: 10.1016/j.molmet.2015.08.001] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Revised: 07/30/2015] [Accepted: 08/05/2015] [Indexed: 11/30/2022] Open
Abstract
Objectives Peroxisome proliferator-activated receptor γ coactivator 1 (PPARGCA1, PGC-1) transcriptional coactivators control gene programs important for nutrient metabolism. Islets of type 2 diabetic subjects have reduced PGC-1α expression and this is associated with decreased insulin secretion, yet little is known about why this occurs or what role it plays in the development of diabetes. Our goal was to delineate the role and importance of PGC-1 proteins to β-cell function and energy homeostasis. Methods We investigated how nutrient signals regulate coactivator expression in islets and the metabolic consequences of reduced PGC-1α and PGC-1β in primary and cultured β-cells. Mice with inducible β-cell specific double knockout of Pgc-1α/Pgc-1β (βPgc-1 KO) were created to determine the physiological impact of reduced Pgc1 expression on glucose homeostasis. Results Pgc-1α and Pgc-1β expression was increased in primary mouse and human islets by acute glucose and palmitate exposure. Surprisingly, PGC-1 proteins were dispensable for the maintenance of mitochondrial mass, gene expression, and oxygen consumption in response to glucose in adult β-cells. However, islets and mice with an inducible, β-cell-specific PGC-1 knockout had decreased insulin secretion due in large part to loss of the potentiating effect of fatty acids. Consistent with an essential role for PGC-1 in lipid metabolism, β-cells with reduced PGC-1s accumulated acyl-glycerols and PGC-1s controlled expression of key enzymes in lipolysis and the glycerolipid/free fatty acid cycle. Conclusions These data highlight the importance of PGC-1s in coupling β-cell lipid metabolism to promote efficient insulin secretion. Loss of Pgc-1s in adult β-cells decreases insulin secretion in response to glucose/palmitate. Pgc-1α/β is not required to maintain basal mitochondrial mass or oxidative capacity in mature β-cells. Pgc-1α/β regulates expression of the lipolytic enzymes HSL and ATGL in β-cells. Reduced β-cell Pgc-1 causes accumulation of intracellular acyl-glycerols and cholesterol esters.
Collapse
Affiliation(s)
- Daniel Oropeza
- Laboratory of Molecular Mechanisms of Diabetes, Institut de Recherches Cliniques de Montreal (IRCM), 110 Ave des Pins Ouest, Montreal, Quebec, H2W 1R7, Canada ; Department of Anatomy and Cell Biology, McGill University, 845 Rue Sherbrooke Ouest, Montreal, Quebec, H3A 0G4, Canada
| | - Nathalie Jouvet
- Laboratory of Molecular Mechanisms of Diabetes, Institut de Recherches Cliniques de Montreal (IRCM), 110 Ave des Pins Ouest, Montreal, Quebec, H2W 1R7, Canada ; Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Khalil Bouyakdan
- Montreal Diabetes Research Center, CRCHUM, Department of Medicine, University of Montreal, 2900 Boulevard Edouard-Montpetit, Montreal, Quebec, H3T 1J4, Canada
| | - Gabrielle Perron
- Department of Anatomy and Cell Biology, McGill University, 845 Rue Sherbrooke Ouest, Montreal, Quebec, H3A 0G4, Canada
| | - Lea-Jeanne Ringuette
- Department of Anatomy and Cell Biology, McGill University, 845 Rue Sherbrooke Ouest, Montreal, Quebec, H3A 0G4, Canada
| | - Louis H Philipson
- Department of Medicine, University of Chicago, 5801 South Ellis Avenue, Chicago, IL, USA
| | - Robert S Kiss
- Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Vincent Poitout
- Montreal Diabetes Research Center, CRCHUM, Department of Medicine, University of Montreal, 2900 Boulevard Edouard-Montpetit, Montreal, Quebec, H3T 1J4, Canada
| | - Thierry Alquier
- Montreal Diabetes Research Center, CRCHUM, Department of Medicine, University of Montreal, 2900 Boulevard Edouard-Montpetit, Montreal, Quebec, H3T 1J4, Canada
| | - Jennifer L Estall
- Laboratory of Molecular Mechanisms of Diabetes, Institut de Recherches Cliniques de Montreal (IRCM), 110 Ave des Pins Ouest, Montreal, Quebec, H2W 1R7, Canada ; Department of Anatomy and Cell Biology, McGill University, 845 Rue Sherbrooke Ouest, Montreal, Quebec, H3A 0G4, Canada ; Montreal Diabetes Research Center, CRCHUM, Department of Medicine, University of Montreal, 2900 Boulevard Edouard-Montpetit, Montreal, Quebec, H3T 1J4, Canada
| |
Collapse
|
28
|
Priyadarshini M, Villa SR, Fuller M, Wicksteed B, Mackay CR, Alquier T, Poitout V, Mancebo H, Mirmira RG, Gilchrist A, Layden BT. An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion. Mol Endocrinol 2015; 29:1055-66. [PMID: 26075576 DOI: 10.1210/me.2015-1007] [Citation(s) in RCA: 114] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
G protein-coupled receptors have been well described to contribute to the regulation of glucose-stimulated insulin secretion (GSIS). The short-chain fatty acid-sensing G protein-coupled receptor, free fatty acid receptor 2 (FFAR2), is expressed in pancreatic β-cells, and in rodents, its expression is altered during insulin resistance. Thus, we explored the role of FFAR2 in regulating GSIS. First, assessing the phenotype of wild-type and Ffar2(-/-) mice in vivo, we observed no differences with regard to glucose homeostasis on normal or high-fat diet, with a marginally significant defect in insulin secretion in Ffar2(-/-) mice during hyperglycemic clamps. In ex vivo insulin secretion studies, we observed diminished GSIS from Ffar2(-/-) islets relative to wild-type islets under high-glucose conditions. Further, in the presence of acetate, the primary endogenous ligand for FFAR2, we observed FFAR2-dependent potentiation of GSIS, whereas FFAR2-specific agonists resulted in either potentiation or inhibition of GSIS, which we found to result from selective signaling through either Gαq/11 or Gαi/o, respectively. Lastly, in ex vivo insulin secretion studies of human islets, we observed that acetate and FFAR2 agonists elicited different signaling properties at human FFAR2 than at mouse FFAR2. Taken together, our studies reveal that FFAR2 signaling occurs by divergent G protein pathways that can selectively potentiate or inhibit GSIS in mouse islets. Further, we have identified important differences in the response of mouse and human FFAR2 to selective agonists, and we suggest that these differences warrant consideration in the continued investigation of FFAR2 as a novel type 2 diabetes target.
Collapse
Affiliation(s)
- Medha Priyadarshini
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Stephanie R Villa
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Miles Fuller
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Barton Wicksteed
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Charles R Mackay
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Thierry Alquier
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Vincent Poitout
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Helena Mancebo
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Raghavendra G Mirmira
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Annette Gilchrist
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| | - Brian T Layden
- Division of Endocrinology, Metabolism, and Molecular Medicine (M.P., S.R.V., M.F., B.T.L.), Northwestern University, Chicago, Illinois 60611; Kovler Diabetes Center (B.W.), The University of Chicago, Chicago, Illinois 60637; Monash University (C.R.M.), Clayton, Victoria 3800, Australia; Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Department of Medicine (T.A., V.P.), University of Montreal, Quebec, H2X 0A9 Canada; Multispan (H.M.), Hayward, California 94545; Department of Pediatrics and the Herman B Wells Center for Pediatric Research (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 4602; Department of Biochemistry and Molecular Biology (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (R.G.M.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmaceutical Sciences (A.G.), Midwestern University, Downers Grove, Illinois 60515; and Jesse Brown Veterans Affairs Medical Center (B.T.L.), Chicago, Illinois 60612
| |
Collapse
|
29
|
Bouyakdan K, Taïb B, Budry L, Zhao S, Rodaros D, Neess D, Mandrup S, Faergeman NJ, Alquier T. A novel role for central ACBP/DBI as a regulator of long-chain fatty acid metabolism in astrocytes. J Neurochem 2015; 133:253-65. [PMID: 25598214 DOI: 10.1111/jnc.13035] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 12/15/2014] [Accepted: 01/08/2015] [Indexed: 12/29/2022]
Abstract
Acyl-CoA-binding protein (ACBP) is a ubiquitously expressed protein that binds intracellular acyl-CoA esters. Several studies have suggested that ACBP acts as an acyl-CoA pool former and regulates long-chain fatty acids (LCFA) metabolism in peripheral tissues. In the brain, ACBP is known as Diazepam-Binding Inhibitor, a secreted peptide acting as an allosteric modulator of the GABAA receptor. However, its role in central LCFA metabolism remains unknown. In the present study, we investigated ACBP cellular expression, ACBP regulation of LCFA intracellular metabolism, FA profile, and FA metabolism-related gene expression using ACBP-deficient and control mice. ACBP was mainly found in astrocytes with high expression levels in the mediobasal hypothalamus. We demonstrate that ACBP deficiency alters the central LCFA-CoA profile and impairs unsaturated (oleate, linolenate) but not saturated (palmitate, stearate) LCFA metabolic fluxes in hypothalamic slices and astrocyte cultures. In addition, lack of ACBP differently affects the expression of genes involved in FA metabolism in cortical versus hypothalamic astrocytes. Finally, ACBP deficiency increases FA content and impairs their release in response to palmitate in hypothalamic astrocytes. Collectively, these findings reveal for the first time that central ACBP acts as a regulator of LCFA intracellular metabolism in astrocytes. Acyl-CoA-binding protein (ACBP) or diazepam-binding inhibitor is a secreted peptide acting centrally as a GABAA allosteric modulator. Using brain slices, cortical, and hypothalamic astrocyte cultures from ACBP KO mice, we demonstrate that ACBP mainly localizes in astrocytes and regulates unsaturated but not saturated long-chain fatty acids (LCFA) metabolism. In addition, ACBP deficiency alters FA metabolism-related genes and results in intracellular FA accumulation while affecting their release. Our results support a novel role for ACBP in brain lipid metabolism. FA, fatty acids; KO, knockout; PL, phospholipids; TAG, triacylglycerol.
Collapse
Affiliation(s)
- Khalil Bouyakdan
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montreal, Quebec, Canada; Department of Biochemistry, University of Montreal, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Pepin E, Higa A, Schuster-Klein C, Bernard C, Sulpice T, Guardiola B, Chevet E, Alquier T. Deletion of apoptosis signal-regulating kinase 1 (ASK1) protects pancreatic beta-cells from stress-induced death but not from glucose homeostasis alterations under pro-inflammatory conditions. PLoS One 2014; 9:e112714. [PMID: 25383781 PMCID: PMC4226582 DOI: 10.1371/journal.pone.0112714] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Accepted: 10/14/2014] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Type 2 diabetes is characterized by pancreatic beta-cell dysfunction and is associated with low-grade inflammation. Recent observations suggest that apoptosis signal-regulating kinase 1 (ASK1) is involved in beta-cell death in response to different stressors. In this study, we tested whether ASK1 deficiency protects beta-cells from glucolipotoxic conditions and cytokines treatment or from glucose homeostasis alteration induced by endotoxemia. METHODOLOGY/PRINCIPAL FINDINGS Insulin secretion was neither affected upon shRNA-mediated downregulation of ASK1 in MIN6 cells nor in islets from ASK1-deficient mice. ASK1 silencing in MIN6 cells and deletion in islets did not prevent the deleterious effect of glucolipotoxic conditions or cytokines on insulin secretion. However, it protected MIN6 cells from death induced by ER stress or palmitate and islets from short term caspase activation in response to cytokines. Moreover, endotoxemia induced by LPS infusion increased insulin secretion during hyperglycemic clamps but the response was similar in wild-type and ASK1-deficient mice. Finally, insulin sensitivity in the presence of LPS was not affected by ASK1-deficiency. CONCLUSIONS/SIGNIFICANCE Our study demonstrates that ASK1 is not involved in beta-cell function and dysfunction but controls stress-induced beta-cell death.
Collapse
Affiliation(s)
| | - Arisa Higa
- Inserm U1053, Team Endoplasmic Reticulum Stress and Cancer, Université de Bordeaux, Bordeaux, France, 33076
| | | | | | - Thierry Sulpice
- Betagenex Inc, Laval, QC, Canada, H7V5B7
- Physiogenex SAS, Labège, France, 31670
| | | | - Eric Chevet
- Inserm U1053, Team Endoplasmic Reticulum Stress and Cancer, Université de Bordeaux, Bordeaux, France, 33076
| | - Thierry Alquier
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), and Departments of Medicine, Biochemistry and Cell Biology and Pathology, Université de Montréal, Montréal, QC, Canada, H3T 1J4
- * E-mail:
| |
Collapse
|
31
|
Fergusson G, Ethier M, Guévremont M, Chrétien C, Attané C, Joly E, Fioramonti X, Prentki M, Poitout V, Alquier T. Defective insulin secretory response to intravenous glucose in C57Bl/6J compared to C57Bl/6N mice. Mol Metab 2014; 3:848-54. [PMID: 25506550 PMCID: PMC4264561 DOI: 10.1016/j.molmet.2014.09.006] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Revised: 09/16/2014] [Accepted: 09/18/2014] [Indexed: 12/01/2022] Open
Abstract
Objective The C57Bl/6J (Bl/6J) mouse is the most widely used strain in metabolic research. This strain carries a mutation in nicotinamide nucleotide transhydrogenase (Nnt), a mitochondrial enzyme involved in NADPH production, which has been suggested to lead to glucose intolerance and beta-cell dysfunction. However, recent reports comparing Bl/6J to Bl/6N (carrying the wild-type Nnt allele) under normal diet have led to conflicting results using glucose tolerance tests. Thus, we assessed glucose-stimulated insulin secretion (GSIS), insulin sensitivity, clearance and central glucose-induced insulin secretion in Bl/6J and N mice using gold-standard methodologies. Methods GSIS was measured using complementary tests (oral and intravenous glucose tolerance tests) and hyperglycemic clamps. Whole-body insulin sensitivity was assessed using euglycemic-hyperinsulinemic clamps. Neurally-mediated insulin secretion was measured during central hyperglycemia. Results Bl/6J mice have impaired GSIS compared to Bl/6N when glucose is administered intravenously during both a tolerance test and hyperglycemic clamp, but not in response to oral glucose. First and second phases of GSIS are altered without changes in whole body insulin sensitivity, insulin clearance, beta-cell mass or central response to glucose, thereby demonstrating defective beta-cell function in Bl/6J mice. Conclusions The Bl/6J mouse strain displays impaired insulin secretion. These results have important implications for choosing the appropriate test to assess beta-cell function and background strain in genetically modified mouse models.
Collapse
Affiliation(s)
- Grace Fergusson
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC H3T 1J4, Canada ; Rodent Metabolic Phenotyping Core of Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada
| | - Mélanie Ethier
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC H3T 1J4, Canada ; Rodent Metabolic Phenotyping Core of Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada
| | - Mélanie Guévremont
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC H3T 1J4, Canada ; Imaging and Cell Biology Core of Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada
| | - Chloé Chrétien
- Centre des Sciences du Goût et de l'Alimentation, Unité Mixte de Recherche CNRS, INRA, Université de Bourgogne, Dijon, France
| | - Camille Attané
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Erik Joly
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC H3T 1J4, Canada ; Imaging and Cell Biology Core of Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada
| | - Xavier Fioramonti
- Centre des Sciences du Goût et de l'Alimentation, Unité Mixte de Recherche CNRS, INRA, Université de Bourgogne, Dijon, France
| | - Marc Prentki
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC H3T 1J4, Canada ; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada ; Department of Nutrition, Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Vincent Poitout
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC H3T 1J4, Canada ; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada ; Department of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Thierry Alquier
- Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC H3T 1J4, Canada ; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada ; Department of Pathology and Cell Biology, Université de Montréal, Montréal, QC H3T 1J4, Canada ; Department of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada
| |
Collapse
|
32
|
Chan JSD, Abdo S, Ghosh A, Alquier T, Chenier I, Filep JG, Ingelfinger JR, Zhang SL, Ross EA, Willenberg BJ, Oca-Cossio J, Clapp WL, Terada N, Abrahamson DR, Ellison GW, Matthews CE, Batich CD, Ihoriya C, Satoh M, Sasaki T, Kashihara N, Piwkowska A, Rogacka D, Angielski S, Jankowski M, Pontrelli P, Conserva F, Papale M, Accetturo M, Gigante M, Vocino G, Dipalma AM, Grandaliano G, Di Paolo S, Gesualdo L, Franzen S, Pihl L, Khan N, Gustafsson H, Palm F, Koszegi S, Hodrea J, Lenart L, Hosszu A, Wagner L, Vannay A, Tulassay T, Szabo A, Fekete A, Aoki R, Sekine F, Kikuchi K, Miyazaki S, Yamashita Y, Itoh Y, Kolling M, Park JK, Haller H, Thum T, Lorenzen J, Hirayama A, Yoh K, Ueda A, Itoh H, Owada S, Kokeny G, Szabo L, Fazekas K, Rosivall L, Mozes MM, Kim Y, Koh ES, Lim JH, Kim MY, Chang YS, Park CW, Kim Y, Kim HW, Kim MY, Lim JH, Chang YS, Park CW, Shin BC, Kim HL, Chung JH, Chan JS, Wu TC, Chen JW, Rogacka D, Piwkowska A, Angielski S, Jankowski M, Clotet S, Soler MJ, Rebull M, Pascual J, Riera M, Patinha D, Afonso J, Sousa T, Morato M, Albino-Teixeira A, Kim H, Min HS, Kang MJ, Kim JE, Lee JE, Kang YS, Cha DR, Jo YI, Seo EH, Kim JD, Lee SH, Jorge L, Silva KAS, Luiz RS, Rampaso RR, Lima W, Cunha TS, Schor N, Lee HJ, Park JY, Kim SK, Moon JY, Lee SH, Ihm CG, Lee TW, Jeong KH, Moon JY, Kim S, Park JY, Kim SY, Kim YG, Jeong KH, Lee SH, Ihm CG, Marques C, Mega C, Goncalves A, Rodrigues-Santos P, Teixeira-Lemos E, Teixeira F, Fontes Ribeiro C, Reis F, Fernandes R, Sutariya BK, Badgujar LB, Kshtriya AA, Saraf MN, Chiu CH, Lee WC, Chau YY, Lee LC, Lee CT, Chen JB, Dahan I, Nakhoul F, Thawho N, Ben-Itzhaq O, Levy AP, Conserva F, Pontrelli P, Accetturo M, Cordisco G, Fiorentino L, Federici M, Grandaliano G, Di Paolo S, Gesualdo L, Wystrychowski G, Havel PJ, Graham JL, Zukowska-Szczechowska E, Obuchowicz E, Psurek A, Grzeszczak W, Wystrychowski A, Clotet S, Soler MJ, Rebull M, Gimeno J, Pascual J, Riera M, Almeida BZD, Seraphim DCC, Punaro G, Nascimento M, Mouro M, Lanzoni VP, Lopes GS, Higa EMS, Roca-Ho H, Riera M, Marquez E, Pascual J, Soler MJ. DIABETES EXPERIMENTAL. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Taïb B, Bouyakdan K, Hryhorczuk C, Rodaros D, Fulton S, Alquier T. Glucose regulates hypothalamic long-chain fatty acid metabolism via AMP-activated kinase (AMPK) in neurons and astrocytes. J Biol Chem 2013; 288:37216-29. [PMID: 24240094 DOI: 10.1074/jbc.m113.506238] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Hypothalamic controls of energy balance rely on the detection of circulating nutrients such as glucose and long-chain fatty acids (LCFA) by the mediobasal hypothalamus (MBH). LCFA metabolism in the MBH plays a key role in the control of food intake and glucose homeostasis, yet it is not known if glucose regulates LCFA oxidation and esterification in the MBH and, if so, which hypothalamic cell type(s) and intracellular signaling mechanisms are involved. The aim of this study was to determine the impact of glucose on LCFA metabolism, assess the role of AMP-activated Kinase (AMPK), and to establish if changes in LCFA metabolism and its regulation by glucose vary as a function of the kind of LCFA, cell type, and brain region. We show that glucose inhibits palmitate oxidation via AMPK in hypothalamic neuronal cell lines, primary hypothalamic astrocyte cultures, and MBH slices ex vivo but not in cortical astrocytes and slice preparations. In contrast, oleate oxidation was not affected by glucose or AMPK inhibition in MBH slices. In addition, our results show that glucose increases palmitate, but not oleate, esterification into neutral lipids in neurons and MBH slices but not in hypothalamic astrocytes. These findings reveal for the first time the metabolic fate of different LCFA in the MBH, demonstrate AMPK-dependent glucose regulation of LCFA oxidation in both astrocytes and neurons, and establish metabolic coupling of glucose and LCFA as a distinguishing feature of hypothalamic nuclei critical for the control of energy balance.
Collapse
Affiliation(s)
- Bouchra Taïb
- From the Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Universite de Montreal and
| | | | | | | | | | | |
Collapse
|
34
|
Honoré JC, Kooli A, Hamel D, Alquier T, Rivera JC, Quiniou C, Hou X, Kermorvant-Duchemin E, Hardy P, Poitout V, Chemtob S. Fatty acid receptor Gpr40 mediates neuromicrovascular degeneration induced by transarachidonic acids in rodents. Arterioscler Thromb Vasc Biol 2013; 33:954-61. [PMID: 23520164 DOI: 10.1161/atvbaha.112.300943] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE Nitro-oxidative stress exerts a significant role in the genesis of hypoxic-ischemic (HI) brain injury. We previously reported that the ω-6 long chain fatty acids, transarachidonic acids (TAAs), which are nitrative stress-induced nonenzymatically generated arachidonic acid derivatives, trigger selective microvascular endothelial cell death in neonatal neural tissue. The primary molecular target of TAAs remains unidentified. GPR40 is a G protein-coupled receptor activated by long chain fatty acids, including ω-6; it is highly expressed in brain, but its functions in this tissue are largely unknown. We hypothesized that TAAs play a significant role in neonatal HI-induced cerebral microvascular degeneration through GPR40 activation. APPROACH AND RESULTS Within 24 hours of a HI insult to postnatal day 7 rat pups, a cerebral infarct and a 40% decrease in cerebrovascular density was observed. These effects were associated with an increase in nitrative stress markers (3-nitrotyrosine immunoreactivity and TAA levels) and were reduced by treatment with nitric oxide synthase inhibitor. GPR40 was expressed in rat pup brain microvasculature. In vitro, in GPR40-expressing human embryonic kidney (HEK)-293 cells, [(14)C]-14E-AA (radiolabeled TAA) bound specifically, and TAA induced calcium transients, extracellular signal-regulated kinase 1/2 phosphorylation, and proapoptotic thrombospondin-1 expression. In vivo, intracerebroventricular injection of TAAs triggered thrombospondin-1 expression and cerebral microvascular degeneration in wild-type mice, but not in GPR40-null congeners. Additionally, HI-induced neurovascular degeneration and cerebral infarct were decreased in GPR40-null mice. CONCLUSIONS GPR40 emerges as the first identified G protein-coupled receptor conveying actions of nonenzymatically generated nitro-oxidative products, specifically TAAs, and is involved in (neonatal) HI encephalopathy.
Collapse
Affiliation(s)
- Jean-Claude Honoré
- Department of Pediatrics, Research Center-CHU Ste-Justine, Montréal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Wauquier F, Philippe C, Léotoing L, Mercier S, Davicco MJ, Lebecque P, Guicheux J, Pilet P, Miot-Noirault E, Poitout V, Alquier T, Coxam V, Wittrant Y. The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem 2013; 288:6542-51. [PMID: 23335512 DOI: 10.1074/jbc.m112.429084] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The mechanisms linking fat intake to bone loss remain unclear. By demonstrating the expression of the free fatty acid receptor G-coupled protein receptor 40 (GPR40) in bone cells, we hypothesized that this receptor may play a role in mediating the effects of fatty acids on bone remodeling. Using micro-CT analysis, we showed that GPR40(-/-) mice exhibit osteoporotic features suggesting a positive role of GPR40 on bone density. In primary cultures of bone marrow, we showed that GW9508, a GRP40 agonist, abolished bone-resorbing cell differentiation. This alteration of the receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation occurred via the inhibition of the nuclear factor κB (NF-κB) signaling pathway as demonstrated by decrease in gene reporter activity, inhibitor of κB kinase (IKKα/β) activation, inhibitor of κB (IkBα) phosphorylation, and nuclear factor of activated T cells 1 (NFATc1) expression. The GPR40-dependent effect of GW9508 was confirmed using shRNA interference in osteoclast precursors and GPR40(-/-) primary cell cultures. In addition, in vivo administration of GW9508 counteracted ovariectomy-induced bone loss in wild-type but not GPR40(-/-) mice, enlightening the obligatory role of the GPR40 receptor. Then, in a context of growing prevalence of metabolic and age-related bone disorders, our results demonstrate for the first time in translational approaches that GPR40 is a relevant target for the design of new nutritional and therapeutic strategies to counter bone complications.
Collapse
Affiliation(s)
- Fabien Wauquier
- Institut National de la Recherche Agronomique, Unité Mixte de Recherche 1019, Unité de Nutrition Humaine, Centre de Recherche en Nutrition Humaine Auvergne, F-63009 Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Kawashima J, Alquier T, Tsuji Y, Peroni OD, Kahn BB. Ca2+/calmodulin-dependent protein kinase kinase is not involved in hypothalamic AMP-activated protein kinase activation by neuroglucopenia. PLoS One 2012; 7:e36335. [PMID: 22590531 PMCID: PMC3349669 DOI: 10.1371/journal.pone.0036335] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2012] [Accepted: 04/03/2012] [Indexed: 11/18/2022] Open
Abstract
Hypoglycemia and neuroglucopenia stimulate AMP-activated protein kinase (AMPK) activity in the hypothalamus and this plays an important role in the counterregulatory responses, i.e. increased food intake and secretion of glucagon, corticosterone and catecholamines. Several upstream kinases that activate AMPK have been identified including Ca2+/Calmodulin-dependent protein kinase kinase (CaMKK), which is highly expressed in neurons. However, the involvement of CaMKK in neuroglucopenia-induced activation of AMPK in the hypothalamus has not been tested. To determine whether neuroglucopenia-induced AMPK activation is mediated by CaMKK, we tested whether STO-609 (STO), a CaMKK inhibitor, would block the effects of 2-deoxy-D-glucose (2DG)-induced neuroglucopenia both ex vivo on brain sections and in vivo. Preincubation of rat brain sections with STO blocked KCl-induced α1 and α2-AMPK activation but did not affect AMPK activation by 2DG in the medio-basal hypothalamus. To confirm these findings in vivo, STO was pre-administrated intracerebroventricularly (ICV) in rats 30 min before 2DG ICV injection (40 µmol) to induce neuroglucopenia. 2DG-induced neuroglucopenia lead to a significant increase in glycemia and food intake compared to saline-injected control rats. ICV pre-administration of STO (5, 20 or 50 nmol) did not affect 2DG-induced hyperglycemia and food intake. Importantly, activation of hypothalamic α1 and α2-AMPK by 2DG was not affected by ICV pre-administration of STO. In conclusion, activation of hypothalamic AMPK by 2DG-induced neuroglucopenia is not mediated by CaMKK.
Collapse
Affiliation(s)
- Junji Kawashima
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Thierry Alquier
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Youki Tsuji
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Odile D. Peroni
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Barbara B. Kahn
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|
38
|
Sorensen CM, Ding J, Zhang Q, Alquier T, Zhao R, Mueller PW, Smith RD, Metz TO. Perturbations in the lipid profile of individuals with newly diagnosed type 1 diabetes mellitus: lipidomics analysis of a Diabetes Antibody Standardization Program sample subset. Clin Biochem 2010; 43:948-56. [PMID: 20519132 DOI: 10.1016/j.clinbiochem.2010.04.075] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2010] [Revised: 04/01/2010] [Accepted: 04/29/2010] [Indexed: 01/12/2023]
Abstract
OBJECTIVES To characterize the lipid profile of individuals with newly diagnosed type 1 diabetes mellitus using LC-MS-based lipidomics and the accurate mass and time (AMT) tag approach. DESIGN AND METHODS Lipids were extracted from plasma and sera of 10 subjects from the Diabetes Antibody Standardization Program (years 2000-2005) and 10 non-diabetic subjects and analyzed by capillary liquid chromatography coupled with a hybrid ion-trap-Fourier transform ion cyclotron resonance mass spectrometer. Lipids were identified and quantified using the AMT tag approach. RESULTS Five hundred fifty-nine lipid features differentiated (q<0.05) diabetic from healthy individuals in a partial least-squares analysis, characterizing individuals with recently diagnosed type 1 diabetes mellitus. CONCLUSIONS A lipid profile associated with newly diagnosed type 1 diabetes may aid in further characterization of biochemical pathways involved in lipid regulation or mobilization.
Collapse
Affiliation(s)
- Christina M Sorensen
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99352, USA
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Alquier T, Peyot ML, Latour MG, Kebede M, Sorensen CM, Gesta S, Ronald Kahn C, Smith RD, Jetton TL, Metz TO, Prentki M, Poitout V. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 2009; 58:2607-15. [PMID: 19720802 PMCID: PMC2768167 DOI: 10.2337/db09-0362] [Citation(s) in RCA: 110] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVE The G-protein-coupled receptor GPR40 mediates fatty acid potentiation of glucose-stimulated insulin secretion, but its contribution to insulin secretion in vivo and mechanisms of action remain uncertain. This study was aimed to ascertain whether GPR40 controls insulin secretion in vivo and modulates intracellular fuel metabolism in islets. RESEARCH DESIGN AND METHODS Insulin secretion and sensitivity were assessed in GPR40 knockout mice and their wild-type littermates by hyperglycemic clamps and hyperinsulinemic euglycemic clamps, respectively. Transcriptomic analysis, metabolic studies, and lipid profiling were used to ascertain whether GPR40 modulates intracellular fuel metabolism in islets. RESULTS Both glucose- and arginine-stimulated insulin secretion in vivo were decreased by approximately 60% in GPR40 knockout fasted and fed mice, without changes in insulin sensitivity. Neither gene expression profiles nor intracellular metabolism of glucose and palmitate in isolated islets were affected by GPR40 deletion. Lipid profiling of isolated islets revealed that the increase in triglyceride and decrease in lyso-phosphatidylethanolamine species in response to palmitate in vitro was similar in wild-type and knockout islets. In contrast, the increase in intracellular inositol phosphate levels observed in wild-type islets in response to fatty acids in vitro was absent in knockout islets. CONCLUSIONS These results indicate that deletion of GPR40 impairs insulin secretion in vivo not only in response to fatty acids but also to glucose and arginine, without altering intracellular fuel metabolism in islets, via a mechanism that may involve the generation of inositol phosphates downstream of GPR40 activation.
Collapse
Affiliation(s)
- Thierry Alquier
- Montréal Diabetes Research Center, Research Centre of the Montréal University Hospital, University of Montréal, Montréal, QC, Canada
- Department of Medicine, University of Montréal, Montréal, QC, Canada
| | - Marie-Line Peyot
- Montréal Diabetes Research Center, Research Centre of the Montréal University Hospital, University of Montréal, Montréal, QC, Canada
| | - Martin G. Latour
- Montréal Diabetes Research Center, Research Centre of the Montréal University Hospital, University of Montréal, Montréal, QC, Canada
| | - Melkam Kebede
- Montréal Diabetes Research Center, Research Centre of the Montréal University Hospital, University of Montréal, Montréal, QC, Canada
- Department of Medicine, University of Montréal, Montréal, QC, Canada
| | - Christina M. Sorensen
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington
| | - Stephane Gesta
- Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts
| | - C. Ronald Kahn
- Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts
| | - Richard D. Smith
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington
| | - Thomas L. Jetton
- Division of Endocrinology, Diabetes, and Metabolism, University of Vermont College of Medicine, Burlington, Vermont
| | - Thomas O. Metz
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington
| | - Marc Prentki
- Montréal Diabetes Research Center, Research Centre of the Montréal University Hospital, University of Montréal, Montréal, QC, Canada
- Department of Nutrition, University of Montréal, Montréal, QC, Canada
| | - Vincent Poitout
- Montréal Diabetes Research Center, Research Centre of the Montréal University Hospital, University of Montréal, Montréal, QC, Canada
- Department of Medicine, University of Montréal, Montréal, QC, Canada
- Corresponding author: Vincent Poitout,
| |
Collapse
|
40
|
Abstract
G-protein coupled receptors (GPCRs) are targets of approximately 30% of currently marketed drugs. Over the last few years, a number of GPCRs expressed in pancreatic beta-cells and activated by lipids have been discovered. GPR40 was shown to be activated by medium- to long-chain fatty acids (FAs). It has since been shown that GPR40 contributes to FA amplification of glucose-induced insulin secretion. Although some controversy still exists as to whether GPR40 agonists or antagonists should be designed as novel type 2 diabetes drugs, data obtained in our laboratory and others strongly suggest that GPR40 agonism might represent a valuable therapeutic approach. GPR119 is expressed in pancreatic beta-cells and enteroendocrine L-cells, and augments circulating insulin levels both through its direct insulinotropic action on beta-cells and through FA stimulation of glucagon-like peptide 1 (GLP-1) secretion. GPR120 is expressed in L-cells and was also shown to mediate FA-stimulated GLP-1 release. Finally, GPR41 and GPR43 are receptors for short-chain FAs and may indirectly regulate beta-cell function via adipokine secretion. Although the discovery of these various lipid receptors opens new and exciting avenues of research for drug development, a number of questions regarding their mechanisms of action and physiological roles remain to be answered.
Collapse
Affiliation(s)
- M A Kebede
- Montréal Diabetes Research Center, CRCHUM, QC, Canada
| | | | | | | |
Collapse
|
41
|
Affiliation(s)
- Thierry Alquier
- From the Montreal Diabetes Research Center, Research Center of the University of Montreal Hospital Center (CRCHUM), and Department of Medicine, University of Montreal, Montreal, Quebec, Canada
| | - Vincent Poitout
- From the Montreal Diabetes Research Center, Research Center of the University of Montreal Hospital Center (CRCHUM), and Department of Medicine, University of Montreal, Montreal, Quebec, Canada
- Corresponding author: Vincent Poitout,
| |
Collapse
|
42
|
Abstract
OBJECTIVE The G-protein-coupled receptor GPR40 is expressed in pancreatic beta-cells and is activated by long-chain fatty acids. Gene deletion studies have shown that GPR40 mediates, at least in part, fatty acid-amplification of glucose-induced insulin secretion (GSIS) but is not implicated in GSIS itself. However, the role of GPR40 in the long-term effects of fatty acids on insulin secretion remains controversial. This study aimed to test the hypothesis that GPR40 plays a role in insulin secretion after high-fat feeding. RESEARCH DESIGN AND METHOD GPR40 knockout (KO) mice on a C57BL/6 background and their wild-type (WT) littermates were fed a high-fat diet (HFD) for 11 weeks. Glucose tolerance, insulin tolerance, and insulin secretion in response to glucose and Intralipid were assessed during the course of the diet period. RESULTS GPR40 KO mice had fasting hyperglycemia. They became as obese, glucose intolerant, and insulin resistant as their WT littermates given HFD and developed a similar degree of liver steatosis. Their fasting blood glucose levels increased earlier than those of control mice during the course of the HFD. The remarkable increase in insulin secretory responses to intravenous glucose and Intralipid seen in WT mice after HFD was of much lower magnitude in GPR40 KO mice. CONCLUSIONS GPR40 plays a role not only in fatty acid modulation of insulin secretion, but also in GSIS after high-fat feeding. These observations raise doubts on the validity of a therapeutic approach based on GPR40 antagonism for the treatment of type 2 diabetes.
Collapse
Affiliation(s)
- Melkam Kebede
- Montréal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada
| | | | | | | | | | | |
Collapse
|
43
|
Delghingaro-Augusto V, Latour MG, Peyot ML, Lamontagne J, Lussier R, Alquier T, Mauvais-Jarvis F, Prentki M. Estrogen prevents beta-cell failure and diabetes in ZDF male rats: a role for glycerolipid/fatty acid cycling. Can J Diabetes 2008. [DOI: 10.1016/s1499-2671(08)24208-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
44
|
Kebede M, Alquier T, Latour MG, Semache M, Poitout V. The Fatty-Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat Feeding. Can J Diabetes 2008. [DOI: 10.1016/s1499-2671(08)24147-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, Luo J, Lin DCH, Poitout V. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007; 56:1087-94. [PMID: 17395749 PMCID: PMC1853382 DOI: 10.2337/db06-1532] [Citation(s) in RCA: 222] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Long-chain fatty acids amplify insulin secretion from the pancreatic beta-cell. The G-protein-coupled receptor GPR40 is specifically expressed in beta-cells and is activated by fatty acids; however, its role in acute regulation of insulin secretion in vivo remains unclear. To this aim, we generated GPR40 knockout (KO) mice and examined glucose homeostasis, insulin secretion in response to glucose and Intralipid in vivo, and insulin secretion in vitro after short- and long-term exposure to fatty acids. Our results show that GPR40 KO mice have essentially normal glucose tolerance and insulin secretion in response to glucose. Insulin secretion in response to Intralipid was reduced by approximately 50%. In isolated islets, insulin secretion in response to glucose and other secretagogues was unaltered, but fatty acid potentiation of insulin release was markedly reduced. The Galpha(q/11) inhibitor YM-254890 dose-dependently reduced palmitate potentiation of glucose-induced insulin secretion. Islets from GPR40 KO mice were as sensitive to fatty acid inhibition of insulin secretion upon prolonged exposure as islets from wild-type animals. We conclude that GPR40 contributes approximately half of the full acute insulin secretory response to fatty acids in mice but does not play a role in the mechanisms by which fatty acids chronically impair insulin secretion.
Collapse
Affiliation(s)
- Martin G. Latour
- Montréal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada
| | - Thierry Alquier
- Montréal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada
| | | | - Caroline Tremblay
- Montréal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada
| | - Thomas L. Jetton
- Division of Endocrinology, Diabetes and Metabolism, University of Vermont College of Medicine, Burlington, VT
| | | | | | - Vincent Poitout
- Montréal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada
- Departments of Medicine, Nutrition, and Biochemistry, University of Montréal, Montréal, QC, Canada
| |
Collapse
|
46
|
Alquier T, Kawashima J, Tsuji Y, Kahn BB. Role of hypothalamic adenosine 5'-monophosphate-activated protein kinase in the impaired counterregulatory response induced by repetitive neuroglucopenia. Endocrinology 2007; 148:1367-75. [PMID: 17185376 DOI: 10.1210/en.2006-1039] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Antecedent hypoglycemia blunts counterregulatory responses that normally restore glycemia, a phenomenon known as hypoglycemia-associated autonomic failure (HAAF). The mechanisms leading to impaired counterregulatory responses are largely unknown. Hypothalamic AMP-activated protein kinase (AMPK) acts as a glucose sensor. To determine whether failure to activate AMPK could be involved in the etiology of HAAF, we developed a model of HAAF using repetitive intracerebroventricular (icv) injection of 2-deoxy-D-glucose (2DG) resulting in transient neuroglucopenia in normal rats. Ten minutes after a single icv injection of 2DG, both alpha1- and alpha2-AMPK activities were increased 30-50% in arcuate and ventromedial/dorsomedial hypothalamus but not in other hypothalamic regions, hindbrain, or cortex. Increased AMPK activity persisted in arcuate hypothalamus at 60 min after 2DG injection when serum glucagon and corticosterone levels were increased 2.5- to 3.4-fold. When 2DG was injected icv daily for 4 d, hypothalamic alpha1- and alpha2-AMPK responses were markedly blunted in arcuate hypothalamus, and alpha1-AMPK was also blunted in mediobasal hypothalamus 10 min after 2DG on d 4. Both AMPK isoforms were activated normally in arcuate hypothalamus at 60 min. Counterregulatory hormone responses were impaired by recurrent neuroglucopenia and were partially restored by icv injection of 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside, an AMPK activator, before 2DG. Glycogen content increased 2-fold in hypothalamus after recurrent neuroglucopenia, suggesting that glycogen supercompensation could be involved in down-regulating the AMPK glucose-sensing pathway in HAAF. Thus, activation of hypothalamic AMPK may be important for the full counterregulatory hormone response to neuroglucopenia. Furthermore, impaired or delayed AMPK activation in specific hypothalamic regions may play a critical role in the etiology of HAAF.
Collapse
Affiliation(s)
- Thierry Alquier
- Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, 99 Brookline Avenue, Boston, MA 02215, USA
| | | | | | | |
Collapse
|
47
|
Martin TL, Alquier T, Asakura K, Furukawa N, Preitner F, Kahn BB. Diet-induced Obesity Alters AMP Kinase Activity in Hypothalamus and Skeletal Muscle. J Biol Chem 2006; 281:18933-41. [PMID: 16687413 DOI: 10.1074/jbc.m512831200] [Citation(s) in RCA: 219] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
AMP-activated protein kinase (AMPK) is a key regulator of cellular energy balance and of the effects of leptin on food intake and fatty acid oxidation. Obesity is usually associated with resistance to the effects of leptin on food intake and body weight. To determine whether diet-induced obesity (DIO) impairs the AMPK response to leptin in muscle and/or hypothalamus, we fed FVB mice a high fat (55%) diet for 10-12 weeks. Leptin acutely decreased food intake by approximately 30% in chow-fed mice. DIO mice tended to eat less, and leptin had no effect on food intake. Leptin decreased respiratory exchange ratio in chow-fed mice indicating increased fatty acid oxidation. Respiratory exchange ratio was low basally in high fat-fed mice, and leptin had no further effect. Leptin (3 mg/kg intraperitoneally) increased alpha2-AMPK activity 2-fold in muscle in chow-fed mice but not in DIO mice. Leptin decreased acetyl-CoA carboxylase activity 40% in muscle from chow-fed mice. In muscle from DIO mice, acetyl-CoA carboxylase activity was basally low, and leptin had no further effect. In paraventricular, arcuate, and medial hypothalamus of chow-fed mice, leptin inhibited alpha2-AMPK activity but not in DIO mice. In addition, leptin increased STAT3 phosphorylation 2-fold in arcuate of chow-fed mice, but this effect was attenuated because of elevated basal STAT3 phosphorylation in DIO mice. Thus, DIO in FVB mice alters alpha2-AMPK in muscle and hypothalamus and STAT3 in hypothalamus and impairs further effects of leptin on these signaling pathways. Defective responses of AMPK to leptin may contribute to resistance to leptin action on food intake and energy expenditure in obese states.
Collapse
Affiliation(s)
- Tonya L Martin
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | | | | | | | | |
Collapse
|
48
|
Leloup C, Magnan C, Benani A, Bonnet E, Alquier T, Offer G, Carriere A, Périquet A, Fernandez Y, Ktorza A, Casteilla L, Pénicaud L. Mitochondrial reactive oxygen species are required for hypothalamic glucose sensing. Diabetes 2006; 55:2084-90. [PMID: 16804079 DOI: 10.2337/db06-0086] [Citation(s) in RCA: 121] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The physiological signaling mechanisms that link glucose sensing to the electrical activity in metabolism-regulating hypothalamus are still controversial. Although ATP production was considered the main metabolic signal, recent studies show that the glucose-stimulated signaling in neurons is not totally dependent on this production. Here, we examined whether mitochondrial reactive oxygen species (mROS), which are physiologically generated depending on glucose metabolism, may act as physiological sensors to monitor the glucose-sensing response. Transient increase from 5 to 20 mmol/l glucose stimulates reactive oxygen species (ROS) generation on hypothalamic slices ex vivo, which is reversed by adding antioxidants, suggesting that hypothalamic cells generate ROS to rapidly increase glucose level. Furthermore, in vivo, data demonstrate that both the glucose-induced increased neuronal activity in arcuate nucleus and the subsequent nervous-mediated insulin release might be mimicked by the mitochondrial complex blockers antimycin and rotenone, which generate mROS. Adding antioxidants such as trolox and catalase or the uncoupler carbonyl cyanide m-chlorophenylhydrazone in order to lower mROS during glucose stimulation completely reverses both parameters. In conclusion, the results presented here clearly show that the brain glucose-sensing mechanism involved mROS signaling. We propose that this mROS production plays a key role in brain metabolic signaling.
Collapse
Affiliation(s)
- Corinne Leloup
- UMR 5018-CNRS UPS, Institut L. Bugnard, IFR31, BP 84432, 31 432 Toulouse cedex 4, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1:15-25. [PMID: 16054041 DOI: 10.1016/j.cmet.2004.12.003] [Citation(s) in RCA: 2105] [Impact Index Per Article: 110.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2004] [Revised: 12/17/2004] [Accepted: 12/20/2004] [Indexed: 02/06/2023]
Abstract
The AMP-activated protein kinase (AMPK) is an evolutionarily conserved sensor of cellular energy status, and recent data demonstrate that it also plays a critical role in systemic energy balance. AMPK integrates nutritional and hormonal signals in peripheral tissues and the hypothalamus. It mediates effects of adipokines (leptin, adiponectin, and possibly resistin) in regulating food intake, body weight, and glucose and lipid homeostasis. AMPK is regulated by upstream kinases of which the tumor suppressor, LKB1, is the first to be identified. Complex signaling networks suggest that AMPK may prevent insulin resistance, in part by inhibiting pathways that antagonize insulin signaling. Through signaling, metabolic, and gene expression effects, AMPK enhances insulin sensitivity and fosters a metabolic milieu that may reduce the risk for obesity and type 2 diabetes.
Collapse
Affiliation(s)
- Barbara B Kahn
- Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA.
| | | | | | | |
Collapse
|
50
|
|